Readiness to Change and Smoking Expectancies Among Adult Male Substance Users Currently in Substance Use Treatment by Waters, Aaron French
 i 
READINESS TO CHANGE AND SMOKING EXPECTANCIES 
AMONG ADULT MALE SUBSTANCE USERS CURRENTLY IN 
SUBSTANCE USE TREATMENT  
A Dissertation  
Submitted to the Graduate Faculty of the  
Louisiana State University and  
Agricultural and Mechanical College  
in partial fulfillment of the  
requirements for the degree of  
Doctor of Philosophy  
in  
The Department of Psychology  
by 
Aaron French Waters 
B.S., California Lutheran University, 2014  
M.A., Louisiana State University, 2018  
December 2020 
 
 ii 
ACKNOWLEDGEMENTS 
 I would like to express my gratitude for the many people who have assisted with the 
development and execution of this study. I would like to thank my primary mentor, Dr. Amy 
Copeland, who has provided me with guidance, knowledge, and support throughout this study. I 
am very grateful to have had the opportunity to work under her mentorship. I would like to thank 
my dissertation committee members, Drs. Calamia, Cherry, and Sasser for their assistance and 
feedback in the development of my dissertation. Thank you to my fellow graduate lab members, 
Melanie Roys, Shelby Stewart, and Zachary Harmony, for their help in the collection of data. I 
am forever grateful for your assistance. This study could not have been completed without the 
support of Dr. Copeland’s Smoking and Substance Use Clinical Research Lab at LSU. I would 
like to thank St. Christopher’s Addiction Wellness Center for their assistance with data collection 
and for allowing our research team to collect data at their facility. This study was supported by 
the LSU Department of Psychology Graduate Student Strategic Research Grant. 
  
 
 iii 
TABLE OF CONTENTS 
ACKNOWLEDGEMENTS........................................................................................................ ii 
 
ABSTRACT ............................................................................................................................. iv 
 
INTRODUCTION ......................................................................................................................1 
 
METHODS ............................................................................................................................... 18 
 
RESULTS ................................................................................................................................. 28 
 
DISCUSSION ........................................................................................................................... 43 
 
APPENDIX A. CONSENT FORM ........................................................................................... 56 
 
APPENDIX B. HIPAA AGREEMENT FORM ......................................................................... 60 
 
APPENDIX C. THE RAPID ESTIMATE OF ADULT LITERACY IN MEDICINE — 
SHORT FORM ......................................................................................................................... 61 
 
 APPENDIX D. DEMOGRAPHIC AND SMOKING QUESTIONNAIRE................................ 62 
 
APPENDIX E. SUBSTANCE USE AND MENTAL HEALTH FORM .................................... 64 
 
APPENDIX F. UNIVERSITY OF RHODE ISLAND STAGES OF CHANGE 
ASSESSMENT ......................................................................................................................... 66 
 
APPENDIX G. SMOKING CONSEQUENCES QUESTIONNAIRE – ADULT ....................... 68 
 
APPENDIX H. FAGERSTRÖM TEST FOR NICOTINE DEPENDENCE ............................... 70 
 
APPENDIX I. IRB APPROVAL ............................................................................................... 71 
 
REFERENCES ......................................................................................................................... 72 
 
VITA ........................................................................................................................................ 79 
 
 iv 
ABSTRACT 
 
The primary aims of the current study were to examine if smoking expectancies and readiness to 
quit smoking, important components in predicting smoking behavior and cessation, changed 
across time for adult smokers in substance use treatment. Participants (N = 51) were 
predominantly white (96.1%), adult, male smokers who were admitted to residential substance 
use treatment. Smoking outcome expectancies and readiness to change smoking were assessed 
among participants at treatment entry (n = 51), and subsequently at 30 days (n = 13), 60 days (n 
= 9), and 90 days (n = 3) from treatment entry. Ninety-day follow-up assessments were excluded 
from outcome analyses due to significant participant attrition. At baseline, the majority of 
participants were in the contemplation (40%) or preparation (action) (40%) stage of change for 
smoking cessation. Repeated measures analyses of variance (ANOVAs) revealed a significant 
decrease in health risk and negative affect reduction smoking expectancies across time points. 
Readiness to change smoking did not significantly differ across time points. Existing literature 
on smoking expectancies has shown that elevated health risk beliefs predict cessation treatment 
entry, whereas elevated expectations for negative affect reduction predict relapse after a 
cessation attempt. Findings in the current study suggest that manipulation of health risk 
expectancies at treatment entry may increase engagement in a subsequent cessation attempt. In 
addition, negative affect reduction expectancies may change with the acquisition of alternate 
skills to manage negative affect learned in substance use treatment. Although readiness to change 
smoking did not increase over time in substance use treatment, the majority of smokers at 
baseline were already in the contemplation and preparation stages for quitting smoking. Based on 
the current findings, the optimal time for smoking cessation intervention efforts may be between 
30 to 60 days after entering substance use treatment.  
 1 
INTRODUCTION 
Overview of Smoking 
 Smoking is the leading cause of preventable death in the United States (U.S.), with 
approximately 480,000 deaths each year due to smoking-related causes (USDHHS, 2014). 
Within the last five decades, over 20 million people have died from tobacco-related illnesses in 
the U.S. (USDHHS, 2014). Numerous diseases and health problems are associated with smoking 
and approximately 300 billion dollars per year are lost in the U.S. due to health care 
expenditures/ loss of productivity related to smoking (USDHHS, 2014). Strategies in the U.S. 
have been employed to reduce smoking prevalence, including increased anti-smoking 
advertisements, access to cessation interventions, and taxes on cigarettes (USDHHS, 2014). 
Even though smoking rates in the U.S. have decreased significantly over the past 20 years, 
differences are present among subgroups of smokers. Individuals in substance use treatment 
smoke at much higher rates than the general population (USDHHS, 2014; Ward, Kedia, Webb, 
& Relyea, 2012). Further, among substance abusers, tobacco-related deaths are considerably 
higher when compared to the general population (Bandiera, Anteneh, Le, Delucchi, & Guydish, 
2015). Therefore, researchers need to identify ways to effectively reduce smoking prevalence 
among individuals in substance use treatment.  
Substance Use and Tobacco Mortality 
 Tobacco and substance use both independently contribute to the development of 
psychological and physiological diseases (Grant et al., 2016; Lim et al., 2012; USDHHS, 2014; 
Walker, Pratt, Schoenborn, & Druss, 2017). However, when tobacco and substance use occur 
comorbidly, the combination of the two disorders creates additional psychological and 
physiological conditions, and their comorbid occurrence places the individual at significant risk 
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for premature mortality. Hser, McCarthy, and Anglin (1994) conducted a longitudinal study in 
which they examined mortality rates for patients receiving substance use treatment and found 
that the death rate of smokers was four times more than that of nonsmokers at a 20-year follow-
up. Hurt et al. (1996) conducted a retrospective study in which they examined mortality rates and 
causes of death among those receiving addiction treatment. It was determined that patients in 
addiction treatment were significantly more likely to die of tobacco-related causes rather than 
alcohol (Hurt et al., 1996). While the abuse of alcohol and licit/illicit substances may have more 
apparent short-term consequences than smoking, substance abusers who smoke are at an 
increased risk of dying from tobacco-related complications than from the substance for which 
they are seeking treatment (Hser et al., 1994; Hurt et al., 1996).  
 Oregon death records analyzed from 1999 to 2005 for the general population (e.g., those 
without any reported substance abuse or mental health problems) highlighted the alarming 
mortality statistics for substance abusers who smoke. Bandiera et al. (2015) examined 148,761 
death records in Oregon occurring between 1999 and 2005 in which a physician completed a 
certificate stating whether the role of tobacco was involved in the death. Bandiera et al. (2015) 
identified three distinct categories within the sample of deceased individuals: the general 
population (no mental health history of diagnoses), those with substance abuse problems, those 
with mental health problems, and those with both substance abuse and mental health problems. 
Of the reported deaths in which the cause of death was known to be tobacco-related or not, 
30.7% of deaths in the general population were attributable to tobacco, 30% of deaths in the 
mental health population were attributable to tobacco, 53.6% of deaths in the substance abuse 
population were attributable to tobacco, and 46.8% of deaths in the dual substance abuse and 
mental health problems population were attributable to tobacco (Bandiera et al., 2015). Further 
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analyses revealed that males and females in the substance abuse or dual problem group were 
significantly more likely to die from tobacco-related illnesses compared to the general population 
or those with just mental health problems. Tobacco-related deaths were found to occur more 
frequently at earlier ages (59 years of age and below) among those with substance abuse 
problems, mental health problems, and dual problems. However, for ages 60-69, the trend among 
tobacco-related deaths in these subgroups occurred at similar rates when compared to the general 
population. The high smoking prevalence among substance abusers, as well as the significantly 
increased rates of mortality due to comorbid substance abuse and tobacco use, has compelled 
investigations on how to effectively reduce smoking within this population.  
Cessation Programs in Substance Use Treatment Settings 
  An association between continued smoking and craving/use of other substances has been 
documented within the literature. Among individuals with remitted alcohol use disorder, those 
identified as smokers at a 3-year follow-up were significantly more likely to report relapse to 
alcohol abuse or dependence than nonsmokers (Weinberger, Platt, Jiang, & Goodwin, 2015). 
Recent smoking and decreased confidence to stop smoking have been found to be predictive of 
drinking relapse among patients in concurrent substance abuse and tobacco cessation treatment 
(Holt, Litt, & Cooney, 2012). Research has also highlighted the association between increased 
smoking frequency and increased craving for cocaine and dual craving of cocaine and heroin 
among methadone-maintained outpatients (Epstein, Marrone, Heishman, Schmittner, & Preston, 
2010). A meta-analysis investigating the relationship between cannabis and tobacco identified an 
association between tobacco use in substance abuse treatment and a decreased likelihood of 
abstinence from cannabis (Peters, Budney, & Carroll, 2012). Research also supports that 
resuming or starting to smoke after entering substance abuse treatment is associated with 
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decreased rates of abstinence for the substance in which treatment was initially sought. At a 12-
month follow-up, patients in substance abuse treatment who quit smoking or who were 
nonsmokers tended to report more days abstinent from substances other than tobacco compared 
to those who remained smoking or those who resumed/ started smoking (Kohn, Tsoh, & 
Weisner, 2003). These findings indicate a greater risk of relapse on licit/illicit substances among 
patients who begin to smoke, or lapse, after starting substance abuse treatment (Kohn et al., 
2003).   
 Given the associations identified between continued smoking and increased cravings/ 
decreased rates of abstinence for other substances among those in substance use treatment, there 
have been efforts made to include smoking cessation within substance use treatment settings. 
Thurgood, McNeill, Clark-Carter, and Brose (2016) conducted a meta-analysis examining the 
effectiveness of smoking cessation interventions for adults in substance use treatment or 
recovery. Specifically, they looked at 17 randomized controlled trials (RCTs) that included 
biochemically verified abstinence from smoking at either 6- or 12-month follow-up with 
substance use treatment outcomes included as a secondary aim. Thurgood et al. (2016) identified 
eight alcohol only treatment studies, five alcohol and drug treatment studies, and four drug only 
treatment studies that included an RCT for smoking cessation conducted from 1990 to 2014. Out 
of these 17 identified studies, 5 reported significant effects of smoking cessation (e.g., nicotine 
replacement therapy, behavioral support, and combination) at 6- or 12-month follow-up on 
reducing smoking rates for smokers in substance use treatment. The combination of cognitive-
behavioral therapy, nicotine patch, and nicotine gum was found to produce the highest cessation 
rates at 12-month follow-up when compared to any of these treatments alone or a placebo gum 
condition. Two studies in which smoking cessation included contingency management (i.e., 
 
 5 
providing monetary incentives in exchange for biochemically verified abstinence) and relapse 
prevention also showed improvements in substance use outcomes. Lastly, none of the 17 studies 
within this meta-analysis reported that smoking cessation adversely affected substance use 
outcomes. These findings are inconsistent with common clinical lore that smoking cessation 
should be discouraged during treatment for substance use disorders, as it may place patients at 
risk for early relapse to their drug of choice. Many substance abuse staff maintain the view that 
coinciding change of both disorders may be too challenging for the individual to cope with at one 
time (Walsh, Bowman, Tzelepis, & Lecathelinais, 2005).   
 Bernstein and Stoduto (1999) conducted one of the first studies in which a smoking 
cessation program was implemented in a substance use treatment context, and that addressed 
staff acceptability of such a program. The study also assessed client and staff attitudes toward a 
smoking cessation program and motivation to quit smoking within the stages of change (J. O. 
Prochaska, Norcross, & DiClemente, 1994). Bernstein and Stoduto (1999) administered a 
choice-based smoking cessation program for staff and clients within a substance use treatment 
center. The staff at the facility, along with the researchers, developed the program so that the 
staff became more knowledgeable about tobacco use and more motivated to introduce a 
cessation program into their treatment setting. The program consisted of a smoking cessation 
awareness component (i.e., education about smoking and smoking/ substance use recovery) 
followed by an available cessation program. The facility was smoke-free, but had designated 
smoking areas on the campus. A majority of staff (98.2%) and clients (87.0%) reported that a 
smoking cessation program within substance use treatment would be a good idea. However, both 
staff and clients also reported that banning smoking from the facility would be problematic 
(Bernstein & Stoduto, 1999). Fifty five point 6% of staff and 38% of clients who smoked entered 
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the cessation program (Bernstein & Stoduto, 1999). Of the clients who participated in the 
cessation program and chose cessation as an end goal (vs. smoking reduction), 17.5% reported 
not smoking in the past 7 days, at the 6-month or 1-year follow-up. Among clients who engaged 
in the cessation program, a greater proportion reported progression versus regression in readiness 
to quit smoking (Bernstein & Stoduto, 1999). Disseminating educational information regarding 
smoking and smoking/ substance abuse among staff and clients may alter attitudes towards the 
inclusion and utilization of cessation in substance use treatment.  
 Past research has identified an underlying ambivalence towards cessation among smokers 
in substance use treatment (Asher et al., 2003; Richter, Hunt, Cupertino, Garrett, & Friedmann, 
2012). As a result, one variable of interest in addressing smoking cessation for those with 
substance use disorders is how to increase the likelihood of patients utilizing available smoking 
cessation services. Guydish et al. (2016) conducted a study in which they sought to determine 
how the inclusion of a readiness group, or a readiness group with the inclusion of contingency 
management, affected rates of attending an available smoking cessation program among smokers 
in substance abuse treatment. The readiness group consisted of personalized feedback, didactic 
presentations, skills training personalized to the stage of change, and a facilitated personalized 
quit attempt with access to nicotine replacement therapy, while the contingency management 
group also included financial incentives. Guydish et al. (2016) determined that the inclusion of 
financial incentives did not increase the likelihood of a patient utilizing smoking cessation 
services. Rather, motivation and quitting rehearsal were predictive of a patient utilizing services 
provided. Furthermore, Guydish et al. (2016) found that after completing the readiness group, 
smokers significantly decreased their daily smoking rate and significantly lowered their nicotine 
dependence level from baseline. While contingency management is an effective method for 
 
 7 
increasing abstinence in substance use populations (Higgins, Silverman, & Heil, 2007), Guydish 
et al. (2016) concluded that financial incentives might not be as important as pre-cessation 
motivational enhancement for smokers in substance abuse treatment. Nevertheless, these 
findings provide evidence that personalized motivational enhancement interventions can 
manipulate ambivalence towards cessation among smokers in substance abuse treatment. 
 Other research has sought to determine the effect of contingency management on 
smoking cessation for those in substance use treatment.  Robles et al. (2005) utilized contingency 
management in a smoking cessation program for women in residential substance use treatment. 
Patients completed biochemically verified measures of smoking at 1-week pre-quit, through 4-
weeks of a cessation program, and then again at 2-weeks post-intervention. Patients submitted 
significantly more negative biochemically verified samples for smoking abstinence during the 
intervention compared to the pre-quit week. However, the effects were no longer significant at 2 
weeks post-intervention. Robles et al. (2005) reported that participants in their study were 
administered bupropion to manage comorbid depression. While bupropion has been found to 
improve cessation outcomes, the effects of other pharmacological treatments found to be 
efficacious (e.g., nicotine replacement therapy) for treating nicotine dependence were not made 
available to participants (Robles et al., 2005). Other research has documented that among 
substance users in treatment, those who successfully quit smoking reported using a combination 
of strategies including prayer, nicotine gum, behavioral and cognitive coping strategies, and 
nicotine fading (gradual reduction in daily smoking rate) (Richter, McCool, Okuyemi, Mayo, & 
Ahluwalia, 2002). Research has determined that among other populations utilizing contingency 
management in combination with usual care (i.e., pharmacological treatment and counseling) is 
significantly efficacious in producing prolonged abstinence from smoking. Kendzor et al. (2015) 
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found that low socioeconomic smokers receiving contingency management in addition to usual 
care were significantly more likely to be abstinent from smoking at a 12-week post quit follow-
up compared to those receiving usual care only. In conclusion, the findings of Robles et al. 
(2005) suggest that contingency management alone may be helpful as a component of smoking 
cessation for smokers in substance use treatment, but that other components of cessation 
treatment (e.g., pharmacological and counseling) may be needed to produce lasting change.  
 Joseph, Willenbring, Nugent, and Nelson (2004) conducted a clinical trial looking at the 
long-term effects of a delayed (6-months) versus concurrent smoking cessation intervention for 
patients in alcohol dependence treatment. While long-term smoking rates were comparable 
between both groups at the 18-month follow-up, there were significant differences in alcohol use 
among groups. Specifically, those in the concurrent interventions had significantly lower alcohol 
abstinence rates at 6, 12, and 18-month follow-ups compared to those in the delayed intervention 
condition (Joseph et al., 2004). The findings of Joseph et al. (2004) provide some evidence that a 
delayed smoking cessation intervention may be better for long-term alcohol outcomes, but 
inconsequential in long-term smoking abstinence. Kalman et al. (2001) compared the long-term 
effects of a delayed (6-week) versus concurrent smoking cessation intervention for male smokers 
in substance abuse treatment. The delayed versus concurrent intervention did not yield 
significantly different outcomes on tobacco abstinence at final follow-up. Collectively, these 
studies indicate that the timing of cessation interventions for smokers in substance abuse 
treatment may be relevant to the successful cessation of both smoking and substance use 
disorders.   
Smoking Expectancies         
 Outcome expectancies, the anticipated reinforcing and punishing effects of a substance 
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play an important role in the initiation, maintenance, and cessation of substance use and smoking 
(Bot, Engels, & Knibbe, 2005; Brandon, Juliano, & Copeland, 1999; Jones, Corbin, & Fromme, 
2001; Leventhal & Schmitz, 2006). A sizeable literature has established smoking outcome 
expectancies as predictive of smoking motivation and consumption, nicotine dependence levels, 
motivation to quit smoking, and cessation outcomes (Brandon & Baker, 1991; Copeland, 
Brandon, & Quinn, 1995; Heinz, Kassel, Berbaum, & Mermelstein, 2010). Indeed, in several 
studies, expectancies have been targeted for change as an intervention strategy for behavior 
change related to both smoking and alcohol use (Copeland & Brandon, 2000; Darkes & 
Goldman, 1998). Brandon and Baker (1991) developed the Smoking Consequences 
Questionnaire (SCQ) to assess smoking expectancies among college students and identified four 
factor-analytically derived, reliable factors named—Negative Consequences  (e.g., health risk, 
addiction sustainment, respiratory irritation, and negative social impression), Positive 
Reinforcement-Sensory Satisfaction (e.g., taste, sensorimotor manipulation, social facilitation, 
positive affect), Negative Reinforcement-Negative Affect Reduction (e.g., anxiety reduction, 
anger/irritability reduction, depression reduction), and Appetite-Weight Control. In the study, 
daily smokers reported higher positive reinforcement and negative reinforcement expectancies 
compared to occasional smokers, ex-smokers, triers, and those who had never smoked. In a 
subsequent study using the SCQ with adult, heavy smokers with considerable smoking 
experience and high levels of nicotine dependence Copeland et al. (1995) identified ten distinct, 
reliable factors and named the revised measure the SCQ-Adult (SCQ-A). The ten factors were 
named Negative Affect Reduction, Stimulation/State Enhancement, Health Risks, Taste/ 
Sensorimotor Manipulation, Social Facilitation, Appetite-Weight Control, Craving 
Reduction/Addiction, Negative Physical Feelings, Boredom Reduction, and Negative Social 
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Impression. Copeland et al. (1995) reported that with increased smoking experience, smoking 
expectancies become more refined and crystalized, consistent with expectancy theory (Goldman, 
Brown, Christiansen, & Smith, 1991). 
 Research has been conducted to determine which expectancies are predictive of cessation 
attempts, successful cessation, and relapse prevention. Lower negative affect reduction 
expectancies and higher health risk expectancies have been found to predict quit attempts and 
successful cessation (Copeland et al., 1995; McCaul et al., 2006; Rose, Chassin, Presson, & 
Sherman, 1996; Wetter et al., 1994). Rose et al. (1996) conducted a longitudinal study with 
young adult smokers and found that higher health consequence beliefs about smoking predicted 
quit attempts among heavy smokers. Furthermore, higher value of health was associated with 
successful cessation (Rose et al., 1996). McCaul et al. (2006) conducted a meta-analysis 
examining studies that identified motives to quit smoking among current smokers, ex-smokers, 
and smokers currently in a cessation program. Smoking-related health consequence beliefs were 
consistently reported as a primary reason for cessation attempts (McCaul et al., 2006). Therefore, 
there is evidence that expectancies regarding smoking-related health consequences are associated 
with motivation to quit smoking. In addition, negative affect reduction expectancies have 
significantly predicted abstinence versus relapse among smokers post-cessation. For example, 
Copeland et al. (1995) found that negative affect reduction expectancies predicted smoking rates 
at 1, 2, 4, and 6 months post-cessation among smokers who had participated in a smoking 
cessation intervention. Further, significant pre- to post-treatment decrease in negative affect 
reduction expectancies was found among abstainers versus relapsers. In another study using the 
SCQ, Wetter et al. (1994) found that higher expectancies for negative reinforcement predicted 
smoking at 1-week post-intervention, whereas higher expectancies for negative consequences 
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(e.g., health risks) significantly predicted abstinence (Wetter et al., 1994). Smoking expectancies 
have been found to change for smokers currently receiving cessation services (Copeland et al., 
1995); however, there is also evidence that expectancies can be directly manipulated. Copeland 
and Brandon (2000) showed adult smokers videos related to smoking-related health risks or 
smoking-related mood management, followed by an interview to personalize the expectancy 
information. Smokers reported lower expectancies for negative affect reduction following the 
mood management manipulation, and smokers who viewed the health risks video reported 
increased motivation to quit smoking.   
 Identifying smoking expectancies unique to those with substance use disorders is an area 
of research that has received some attention. Hendricks, Peters, Thorne, Delucchi, and Hall 
(2014) conducted a study examining smoking expectancies related to adverse outcomes of 
quitting smoking among alcohol and drug users. Hendricks et al. (2014) found that adverse 
outcome expectancies (e.g., “my drug habit would increase if I quit,” “my use of other drugs 
would increase,” “the people close to me would make fun of me for trying to stop smoking,” “I 
would feel like a traitor to my fellow smokers,” “I would look less attractive than before,” “I 
would not look as cool,” and “I would feel like I had been bullied into quitting”) were associated 
with a decreased desire to quit smoking and a decreased likelihood of reporting complete 
abstinence as a goal among those who reported using marijuana or opiates. Interestingly, 
substance users in this study reported that quitting smoking would not only harm their abstinence 
from other substances, but it would also have interpersonal consequences. Smoking expectancies 
for positive and negative reinforcement have also been observed within self-help groups, such as 
Alcoholics Anonymous. Reich, Dietrich, Finlayson, Fischer, and Martin (2008) found that 
smokers attending Alcoholics Anonymous reported negative affect reduction as the most 
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important effect of smoking. The findings of Reich et al. (2008) suggest a potential mechanism 
by which smoking is perpetuated among smokers who have sought treatment for substance use 
disorders. In the early stages of substance use treatment, individuals often find it challenging to 
cope with negative affect. Therefore, smoking may be one of the only strategies they have for 
managing negative affect. However, as they progress in treatment programs, they learn alternate, 
effective coping methods, and as a result, smoking expectancies for negative affect reduction 
may decrease. Further research can identify smoking expectancies that are particularly prevalent 
among those with substance use disorders and determine if and how their expectancies change as 
a function of substance use treatment. Such information can then inform smoking cessation 
interventions and tailor them best to meet the needs of this population of smokers.  
 Rohsenow, Colby, Martin, and Monti (2005) assessed smoking expectancies related to 
substance use among individuals admitted to residential substance abuse treatment. Expectancies 
regarding the interaction of smoking and substance use were assessed. Examples of these 
expectancies are, “Drinking or using drugs results in wanting a cigarette more,” “Smoking gives 
me more desire for alcohol or drugs,” “I have smoked a cigarette in order to try to decrease my 
urge to drink or use drugs,” and “During treatment for my substance abuse problem, I believe 
that I should try to quit smoking.” Positive smoking expectancies were found to be associated 
with smoking and increased substance use as well as smoking being used to combat substance 
use urges (Rohsenow et al., 2005).  
Smoking and Stages of Change 
 The transtheoretical model provides a framework for understanding stages of behavioral 
change and the processes of change that have direct application to several health-related 
behaviors. The transtheoretical model integrates several theories of behavior change, including 
 
 13 
Freudian, Skinnerian, and Rogerian, as well as the model of decision-making and self-efficacy 
theory. Within the transtheoretical model, six stages of change and ten processes that progress 
change have been identified (J. O. Prochaska, Redding, & Evers, 2015). Stages of change include 
precontemplation (e.g., no desire to change behavior in the next 6 months), contemplation (e.g., 
considering making changes in the next 6 months), preparation (e.g., intent on taking action 
soon), action (e.g., apparent modification in lifestyle has been made), maintenance (e.g., working 
to prevent relapse), and termination (e.g., zero temptation for relapse into past behavior). 
Processes that progress behavioral change include consciousness raising (e.g., learning new 
information to support change), dramatic relief (e.g., increased emotional experiences), self-
reevaluation (e.g., assessment of self with and without unhealthy behavior), environmental 
reevaluation (e.g., assessment of unhealthy behavior on the environment), self-liberation (e.g., 
belief that change can be made), social liberation (e.g., changes to the environment that support 
change), counterconditioning (e.g., developing alternative healthy behaviors), stimulus control 
(e.g., removal of cues for unhealthy behavior/ addition of cues to prompt healthy alternatives), 
contingency management (e.g., a reward for engagement in health behavior), and helping 
relationships (e.g., building social support for behavior change) (J. O. Prochaska et al., 2015).  
 Stages of change have been widely documented in tobacco literature regarding smoking 
behavior and smoking cessation (DiClemente & Prochaska, 1982; DiClemente et al., 1991; J. O. 
Prochaska & DiClemente, 1983). Most notably, DiClemente et al. (1991) identified smoking 
habits, smoking history, and follow-up cessation rates across stages of change in smokers in a 
minimal intervention smoking cessation study. As would be expected, preparation stage smokers 
were found to smoke significantly fewer cigarettes, were less nicotine dependent, obtained less 
pleasure from smoking, and reported the greatest number of past quit attempts compared to 
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precontemplators and contemplators (DiClemente et al., 1991). Furthermore, preparation stage 
smokers were found to be most confident in their ability to quit smoking, followed by 
contemplators, and then precontemplators. Preparation stage smokers reported the lowest scores 
of positive aspects of smoking, followed by contemplators, and then precontemplators. For 
reported negative aspects of smoking, precontemplators reported the lowest scores followed by 
contemplators, and then preparation stage smokers (DiClemente et al., 1991). Preparation stage 
smokers were found to be the most active in behavioral and cognitive processes employed to quit 
smoking, with contemplators being more similar to preparation stage smokers on cognitive 
processes, but more similar to precontemplators on behavioral processes. At 1-month follow-up, 
significantly more of the abstainers were initially identified as preparation stage smokers 
compared to contemplators and precontemplators, and at 6-month follow-up, approximately 80% 
of preparation stage smokers reported making a 24-hour quit attempt in the past 6 months 
(DiClemente et al., 1991). Stages of change are predictive of smoking quit attempts and success 
rates in smoking cessation programs. How these stages of change for smoking may evolve for 
those with substance use disorders over the duration of time they are in substance use treatment 
has not been investigated.  
 In the context of smokers in substance use treatment it is likely that readiness to quit 
smoking and motivation for smoking cessation varies throughout substance use treatment. As a 
patient progresses through substance use treatment, he/she is likely to progress through stages of 
change for the substance for which treatment was sought. Given that a patient stays in substance 
use treatment, he/she may fall in action (e.g., apparent modification in lifestyle has been made) 
or maintenance (e.g., working to prevent relapse) stages of change. These stages have been found 
to be associated with the self-liberation, counterconditioning, helping relationships, 
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reinforcement management, and stimulus control processes of change (J. O. Prochaska et al., 
2015). It is possible that the processes of change resulting from engagement in substance use 
treatment may generalize to smoking and progress stage change for smoking behavior. Future 
research examining the indirect affect of engagement in substance use treatment on stages of 
change for smoking may provide insight into the most appropriate time to provide cessation in 
substance use treatment. 
The Present Study 
 Among individuals diagnosed with substance use disorders, smoking rates are 
disproportionality high as compared with the general population (Cookson et al., 2014; 
USDHHS, 2014; Ward et al., 2012), and tobacco-related mortality is significantly increased 
among substance abusers who smoke (Bandiera et al., 2015). Research has identified that 
quitting smoking while quitting other substances, is associated with improved long-term 
abstinence for primary substances of choice (Kohn et al., 2003; J. J. Prochaska, Delucchi, & 
Hall, 2004; Tsoh, Chi, Mertens, & Weisner, 2011). In contrast, there is research supporting that 
postponing smoking cessation during substance use treatment is associated with improved long-
term abstinence for the substance that treatment was initially sought (Joseph et al., 2004). There 
has been a substantial effort in the development of smoking cessation interventions for those in 
substance use treatment. Yet, findings have been inconsistent as to if and how these interventions 
should overlap in order to optimize success in changing both behaviors. As a result, smoking 
cessation has not been consistently made available to smokers in substance use treatment, and 
smoking rates among this population remain disproportionately high.  
 These inconsistencies compelled the current study, in which the primary aim was to 
determine how fundamental constructs, such as smoking expectancies and readiness to change, 
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vary during substance use treatment. Readiness to change has been well documented as a 
predictor of quit attempts and successful cessation among smokers (DiClemente & Prochaska, 
1982; DiClemente et al., 1991; J. O. Prochaska & DiClemente, 1983). Health consequence 
expectancies have been found to predict motivation to quit and quit attempts (McCaul et al., 
2006; Rose et al., 1996) and negative affect reduction expectancies have been found to predict 
continued smoking behavior as well as poor success in cessation programs (Copeland et al., 
1995; Wetter et al., 1994). During substance use treatment, patients are exposed to health-related 
behaviors (e.g., dietary and exercise) and psychoeducation about substance use disorders, and 
they are also taught new coping skills to deal with stress and negative emotions. It was 
anticipated that exposure to health information and the introduction of new coping skills might 
generalize to patients’ smoking behavior in substance use treatment. Based on past research on 
readiness to change and smoking expectancies, the current study examined when substance user 
smokers may be most receptive to engaging in a smoking cessation program during substance 
use treatment. The current study consisted of three specific aims,1) identify changes in readiness 
to quit smoking over the course of substance use treatment, 2) identify changes in health risk 
expectancies over the course of substance use treatment, and 3) identify changes in negative 
affect reduction expectancies over the course of substance use treatment. In relation to aim 1, it 
was hypothesized that readiness to quit smoking would increase over time spent in substance use 
treatment as smokers learn new coping skills and information about the health consequences of 
other substances. Learning new coping skills and information about the health consequences of 
other substances was hypothesized to generalize to smoking behavior, increasing readiness to 
quit. In relation to aim 2, it was hypothesized that health risk expectancies would increase over 
time as smokers in substance use treatment learned about the negative health risks related to their 
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substance of choice, hypothesized to generalize to health risk smoking expectancies. Lastly, in 
relation to aim 3, it was hypothesized that negative affect reduction expectancies would decrease 
over time as smokers in substance use treatment learned new coping strategies to manage 
negative affect, hypothesized to generalize to negative affect reduction smoking expectancies. 
The goal of the current study was to identify how readiness to quit smoking and smoking 
expectancies changed over the course of substance use treatment in order to have a more 
accurate understanding of when the implementation of a cessation program may be most 
beneficial for this population. 
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METHODS 
Participants  
Power Analysis 
 An a priori repeated measures analysis of variance (ANOVA) power analysis was 
conducted using G*Power 3.1 (Faul, Erdfelder, Buchner, & Lang, 2013). Since there were no 
existing studies identified in the literature that were similar to the present study and proposed 
methodology, an estimated medium effect size was used to determine sample size. It was 
determined that a sample size of at least 46 participants was required to detect a medium effect 
(partial eta-squared = 0.03) with power of 0.8, and alpha set at 0.05.  
Recruitment 
 Participants were recruited from St. Christopher’s Addiction Wellness Center in Baton 
Rouge, LA. St. Christopher’s is a multi-modality based substance use treatment center that 
focuses on treating substance use disorders through evidence-based treatments and 12-step 
involvement. St. Christopher’s provides and encourages long-term treatment that can last from 6-
months to 1 year. The first author was checking the electronic medical record (EMR) system 
used by St. Christopher’s several times a week to identify newly admitted patients. When a 
newly admitted patient was identified, a researcher would go to St. Christopher’s and attempt to 
recruit the patient into the study within seven days of a patient’s admittance to treatment. A 
researcher in Baton Rouge had several times scheduled throughout the week to meet with newly 
admitted patients to reduce the possibility of patients not being recruited within seven days of 
admittance to St. Christopher’s. If a patient agreed to participate, the researcher reviewed the 
consent and HIPAA agreement form with the potential participant (See Appendix A for Consent 
Form; See Appendix B for HIPAA Agreement Form).  
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 Criteria for eligibility. In order for participants to be eligible they had to be 1) admitted 
at St. Christopher’s during the dates of data collection; 2) ≥ 18 years of age at the initial study 
visit; 3) a current smoker (i.e., at least weekly smoking and an expired carbon monoxide monitor 
reading of 8 > parts per million); 4) not mandated by court system to attend substance use 
treatment; and 5) able to demonstrate a 7th grade reading level or higher. 
 Criteria for exclusion. Individuals were excluded from the study if they were: 1) 
discharged from St. Christopher’s; 2) < 18 years of age; 3) not current smokers as determined 
above; 4) mandated by court system to attend substance use treatment; or 5) unable to 
demonstrate a 7th grade reading level or higher. 
Measures and Materials 
 All participants completed an assessment of literacy at baseline. All participants 
completed the demographic and smoking questionnaire, breath analysis for carbon monoxide, 
and assessments of readiness to change, smoking expectancies, and nicotine dependence at 
baseline, 30-day, 60-day, and 90-day follow-ups. The first author would access St. Christopher’s 
charts to retrieve substance use and mental health history information for participants.   
Literacy 
 The Rapid Estimate of Adult Literacy in Medicine—Short Form (REALM - SF; 
Arozullah et al., 2007). The REALM – SF is a 7-item word recognition test that provides a valid 
quick assessment of patient health literacy. Additionally, the REALM – SF can be used to 
evaluate grade level reading ability (e.g., 3rd grade and below, fourth to sixth grade, seventh to 
eight grade, and high school). (See Appendix C for the REALM – SF).  
Questionnaire 
 The demographic questionnaire is a brief self-report questionnaire that was used to gather 
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demographic information as well as basic information on current and past smoking behavior. 
(See Appendix D for the Demographic Questionnaire).  
Substance Use and Mental Health Form 
 Newly admitted patients to St. Christopher’s would meet with a psychiatrist or 
psychiatric nurse practitioner for a psychiatric evaluation and psychosocial assessment in which 
diagnoses were made per the Diagnostic and Statistical Manual-5th Edition (DSM-5). Other 
psychosocial assessment information (e.g., number of substance use treatment programs 
attended, last use of any substance, age of first substance use, and longest period of abstinence 
from substances) was retrieved from the intake completed by staff (e.g., counselor or tech) upon 
a patient’s admittance to St. Christopher’s. (See Appendix E for Substance Use and Mental 
Health Form). 
Readiness to Change 
 University of Rhode Island Stages of Change Assessment (URICA; McConnaughy, 
Prochaska, & Velicer, 1983). The URICA is a 32-item self-report questionnaire that measures 
readiness for behavioral change. Four subscales, including precontemplation, contemplation, 
preparation (action), and maintenance are used to compute a total readiness score. The URICA 
has been found to have good reliability with coefficient alpha’s ranging from 0.88 to 0.89 across 
subscales. Of these 32-items, more recent research on the URICA has suggested the omission of 
4-items (1 from each subscale) for a total of 28-items used in the calculation of the total 
readiness score (Carbonari & DiClemente, 2000; DiClemente & Hughes, 1990). Items are rated 
on a 5-point scale ranging from 1, “strongly disagree,” to 5, “strongly agree.” To calculate the 
readiness to change score, the mean scores for all subscales are calculated. The mean score from 
the precontemplation subscale is subtracted from the sum of mean scores of the contemplation, 
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preparation (action), and maintenance subscales to calculate readiness to change. Higher total 
scores are associated with increased readiness to change. The readiness to change score can be 
transformed from a continuous variable to a categorical variable to identify progression through 
stages of change. The URICA is a widely used, reliable and valid measure to assess motivation 
for behavior change in smokers and those with substance use disorders (Norcross, Krebs, & 
Prochaska, 2011). (See Appendix F for the URICA). 
Smoking Expectancies 
 Smoking Consequences Questionnaire – Adult (SCQ - A; Copeland et al., 1995). The 
SCQ-A is a 55-item self-report measure that assesses several smoking expectancies among adult 
smokers. There are ten domains of smoking expectancies, including negative affect reduction, 
stimulation/state enhancement, health risks, taste/sensorimotor manipulation, social facilitation, 
appetite/ weight control, craving/addiction, negative physical feelings, boredom reduction, and 
social impression. For the current study, only the negative affect reduction and health risks 
subscales were included in the main analyses. Items are rated on a 10-point scale ranging from 0, 
“completely unlikely,” to 9, “completely likely” for each domain, with higher scores reflecting 
the increased likelihood of believing an expectancy to occur after smoking. The SCQ-A has been 
found to have great reliability with coefficient alpha’s ranging from 0.97 to 0.78 across domains. 
(See Appendix G for the SCQ – A). 
Smoking 
 Carbon Monoxide Monitor Reading (Benowitz et al., 2002). A carbon monoxide 
monitor is a non-intrusive and well established biochemical measure of assessing current 
smoking status. A participant blows through a tube, which measures parts per million (ppm) of 
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carbon monoxide in expired breath. A cut-off of 8 ppm or above has been established as an 
appropriate cut-off for identifying current smokers. 
 The Fagerström Test for Nicotine Dependence (FTND; Heatherton, Kozlowski, 
Frecker, & Fagerstrom, 1991). The FTND is a 6-item self-report measure that assesses nicotine 
dependence. Different items have different response options (e.g., yes/no vs. categorical 
responses). Each response option is associated with a number of points used to calculate a single 
score. Higher scores are associated with increased nicotine dependence. The FTND has been 
found to have poor internal consistency with a reported coefficient alpha of 0.61. However, 
research has attributed this poor internal consistency to the low number of items within this 
measure. It is widely used within research looking at smoking. (See Appendix H for the FTND). 
Study Procedure 
Initial Visit 
 At the initial meeting, the researcher and participant would first review the consent 
forms, study requirements, and potential risks of participation. If a patient was eligible and 
expressed interest in participating, he was assigned a participant ID and then was administered 
the REALM – SF to assess for literacy. If a participant was able to demonstrate a 7th grade 
reading level or higher he then completed the baseline assessment, including a demographic and 
smoking questionnaire, breath analysis for carbon monoxide level, the URICA, the SCQ – A, 
and the FTND. Participants were then informed that a researcher would come to St. 
Christopher’s to conduct the follow-up appointment 30 days from the prior assessment. 
Participants could be met within 4 days before or after their follow-up assessment date in order 
to provide flexibility in scheduling. After baseline assessments were completed, the first author 
obtained additional information from the patient’s chart, including documentation on substance 
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use and mental health history. This information was transferred onto a hard copy form. Only the 
first author had access to patient charts. The first author completed all Substance Use and Mental 
Health Forms. The Substance Use and Mental Health Forms were stored with other baseline 
assessment measures in a confidential and secure location.  
Thirty- and Sixty-day Assessment 
 At the 30- and 60-day follow-up, participants completed all baseline assessments 
including the demographic and smoking questionnaire, breath analysis for carbon monoxide, and 
the URICA, SCQ – A, and FTND. Upon completion of each follow-up assessment, a researcher 
would come to St. Christopher’s to conduct the next follow-up appointment 30 days from the 
prior assessment. Participants could be met within 4 days before or after their follow-up 
assessment date in order to provide flexibility in scheduling. 
Ninety-day Assessment 
 At the 90-day follow-up, participants followed study protocols outlined in the 30- and 60-
day follow-up visits. After the participant completed the study measures, he was informed to 
contact the researcher with any questions.  
 Revision to Follow-up Assessment Procedure. As data collection proceeded, the 
completion of follow-up assessments became increasingly difficult due to several program 
changes at St. Christopher’s. First, the head admissions counselor resigned from St. 
Christopher’s. This resulted in shorter treatment stays, as the admissions counselor had actively 
recruited patients to commit to long-term treatment. Several staff who had initially agreed to 
assist with data collection were no longer working at St. Christopher’s or were working in other 
positions within the facility. In response to these unexpected difficulties, the protocol for 
collecting follow-up assessments was revised. The research team consulted directly with 
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treatment staff as to how to improve completion of follow-up assessments, and staff suggested 
that the researchers contact on-site staff or counselors prior to follow-up assessments to obtain 
updates on participant phase transition or discharge. Researchers would contact staff or 
counselors several days in advance of follow-up assessments in an attempt to locate participants 
prior to transitions or discharges.  
Confidentiality of Materials 
 Once a participant completed self-report measures, a researcher brought those materials 
to Louisiana State University (LSU) where they were kept in the Smoking and Substance Use 
Research Laboratory in a locked filing cabinet.   
Institutional Review Board 
 The current study was reviewed and approved by the LSU Institutional Review Board 
and the Institutional Review Board at St. Christopher’s Addiction Wellness Center. A Certificate 
of Confidentiality from the National Institute of Drug Abuse was requested and approved to 
protect participant information. A Certificate of Confidentiality provides additional protection to 
participants by allowing the researchers the right “to refuse to disclose identifying information 
on research participants in any civil, criminal, administrative, legislative, or other proceeding, 
whether at the federal, state, or local level.” (National Institute on Drug Abuse, 2015). The 
Certificate of Confidentiality was one additional step taken to ensure data collected was not used 
in a way that could potentially put participants at risk.  
Study Design 
 Readiness to change has been established as a predictor of quit attempts and successful 
cessation among smokers (DiClemente & Prochaska, 1982; DiClemente et al., 1991; J. O. 
Prochaska & DiClemente, 1983). Furthermore, health risk smoking expectancies and negative 
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affect reduction smoking expectancies have been identified as predictors of motivation to quit 
and quit attempts (McCaul et al., 2006; Rose et al., 1996) and have been found to predict 
continued smoking behavior as well as poor success in cessation program (Copeland et al., 1995; 
Wetter et al., 1994). However, to our knowledge, no studies have tracked how readiness to quit 
smoking and these specific smoking expectancies change for smokers in long-term substance use 
treatment. During substance use treatment, smokers learn about health consequences related to 
their primary substance use disorder and effective coping strategies to manage negative affect. It 
was hypothesized that information learned in substance use treatment would generalize to 
smoking behavior, change readiness to quit smoking, and health risk and negative affect 
reduction expectancies over time.  
 The current study consists of three specific aims. The first aim was to identify if readiness 
to quit smoking changed over the course of substance use treatment. The second aim was to 
identify if health risk expectancies changed over the course of substance use treatment. Lastly, 
the third aim was to identify if negative affect reduction expectancies changed over the course of 
substance use treatment. For these aims changes in readiness to quit smoking, health risk 
expectancies, and negative affect reduction expectancies were analyzed separately as they have 
been found to be distinct constructs within the literature in regard to predicting different 
smoking-related behaviors (e.g., intention to quit, continued smoking, and success in cessation).  
Aim 1 
 For aim 1, a longitudinal design was used to identify if readiness to quit smoking changed 
over the course of 90 days in substance use treatment at four predetermined time points.  
 Hypothesis 1.  For aim 1, it was hypothesized that readiness to quit smoking would 
increase over time as a result of smokers in substance use treatment learning new coping skills 
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and information about the negative health risks of their substance of choice. The acquisition of 
skills and information were hypothesized to generalize to smoking behavior, making smokers 
more receptive to quitting smoking and in turn increasing readiness to quit smoking. 
Aim 2 
 For aim 2, a longitudinal design was used to identify if health risk expectancies changed 
over the course of 90 days in substance use treatment at four predetermined time points.  
Hypothesis 2. For aim 2, it was hypothesized that health risk smoking expectancies 
would increase over time as a result of smokers in substance use treatment learning health-
oriented information and information about the negative health effects of other substances. The 
information learned in treatment about the negative health effects of other substances was 
hypothesized to generalize to health risk smoking expectancies. 
Aim 3  
 For aim 3, a longitudinal design was used to identify if negative affect reduction 
expectancies changed over the course of 90 days in substance use treatment at four 
predetermined time points.  
 Hypothesis 3. For aim 3, it was hypothesized that negative affect reduction smoking 
expectancies would decrease over time as a result of smokers in substance use treatment learning 
other coping skills to manage negative affect other than smoking. Coping skills learned to 
manage negative affect were expected to generalize to negative affect reduction smoking 
expectancies.  
Statistical Procedure 
 Before conducting the statistical analyses to test the 3 hypotheses, analyses were 
conducted to identify participants who completed assessments past baseline and which 
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participants had missing data on self-report measures across assessments. Participants identified 
as having completed baseline and one or more follow-up assessments were included in final 
analyses. Comparison analyses were conducted on baseline variables and measures to identify 
significant differences between participants who complete the baseline assessment only and 
participants who completed the baseline assessment and one or more follow-up assessments. 
Mean substitution, a conservative approach, was used to account for missing data on the URICA 
and SCQ-A for aims 1, 2, and 3. Statistical Package for the Social Sciences (SPSS) version 24 
was employed to determine the reliability of measures included, such as the URICA, SCQ-A, 
and FTND. A correlation table was generated to determine if any of the demographic variables 
(age, education, employment, ethnicity), as well as information taken from the Substance Use 
and Mental Health Form including diagnostic variables (substance use disorders and 
psychological disorders), number of substance use treatment programs attended, last use of any 
substance, age of first substance use, and longest period of abstinence from substances were 
correlated with measures used in aims 1, 2, and 3. Baseline variables that correlated with the 
URICA, SCQ-A Health Risks subscale, and SCQ-A Negative Affect Reduction subscale were 
not included in the analyses for aims 1, 2, and 3 due to the small sample size. A second 
correlation table was generated to identify correlations between the variables described above in 
the overall sample.  
 SPSS version 24 was employed to conduct repeated measures ANOVAs for aims 1, 2, 
and 3. Readiness to change, health risk smoking expectancies, and negative affect reduction 
smoking expectancies were the three continuous variables assessed across time. Bonferonni 
correction, the most conservative correction that can be performed, was applied to all repeated 
measures ANOVAs to control for the increased probability of a Type 1 error occurring. 
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RESULTS 
Participant Recruitment and Follow-up 
 Of the 132 patients who were admitted to St. Christopher’s between March 26th, 2019 
and December 12th, 2019, 102 patients were contacted to participate in the current study. Of the 
30 patients who were not contacted, 19 were not reached within seven days from being admitted 
to St. Christopher’s due to researcher availability, 2 were unavailable due to being ill/ 
hospitalized, and 9 decided against entering treatment at St. Christopher’s. Out of the 102 
patients, 52 were eligible and interested in participating, and 50 were excluded. Reasons for 
exclusion included being court-ordered for treatment (n = 4), having a CO reading being below 8 
ppm (n = 2), identifying as a nonsmoker (n = 19), being under 18 years of age (n = 3), and not 
being interested due to a number of reasons (e.g., lack of incentives and persuasion from other 
patients to not participate) (n = 22). During the baseline assessment, one participant was 
excluded due to psychosis, which became apparent after he consented to participate. A total of 
51 participants completed the baseline assessment, 13 completed the 30-day follow-up, 9 
completed the 60-day follow-up, and 3 completed the 90-day follow-up. Some participants who 
completed the 30-day follow-up were not available for the 60-day follow-up, and some of the 
participants who did not complete the 30-day follow-up were later available for the 60-day 
follow-up. Sixteen participants completed the baseline assessment and one or more of the follow-
ups, including the 30-day or 60-day follow-up, or both. These 16 participants were included in 
the analyses to test the 3 hypotheses. Mean substitution was not implemented for the 90-day 
follow-up assessment as so few participants completed this follow-up assessment. See Figure 1 
for participant retention. 
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Figure 1. Participant Retention through Study Phases
Patient Admits to St. Christopher’s Addiction 
Wellness Program 
3/26/19 – 12/12/19
(N = 132 ) 
Patients Not Approached (n = 30)
-Not reached within 7 day  time frame for baseline assessment (n = 19)
-Ill/ Hospitalized (n = 2)
-Patient decided not to admit to St. Christopher’s (n = 9)
Patients Approached and Screened 
for Eligibility 
(n = 102)
Included (n = 51)
Completed Baseline Assessment (n = 51)
Eligible for 30-day Follow-up (n = 51)
Completed 30-day Follow-up (n = 13)
Excluded (n = 38)
-Left treatment (n = 22)
-Unable to complete during time frame window due 
to researcher or participant availability (n = 8)
-Ill/ Hospitalized (n = 7)
-Withdrew (n = 1)
Eligible for 60-day Follow-up ( (n = 28)
-30-day completers (n = 13)
-30-day unable to complete (n = 8)
-30-day Ill/ Hospitalized (n = 7)
Completed 60-day Follow-up (n = 9)
Excluded (n = 19)
-Left treatment (n = 8)
-Unable to complete during time frame window due to 
researcher  or participant availability (n = 8)
-Ill/ Hospitalized (n = 1)
-Withdrew (n = 2)
Eligible for 90-day follow-up (n = 18)
-60-day completers (n = 9)
-60-day unable to complete (n = 8)
-60-day Ill/ Hospitalized (n = 1)
Completed 90-day Follow-up (n = 3)
Excluded (n = 15)
-Left treatment (n = 5)
-Unable to complete during time frame window due to 
researcher or participant availability (n = 7)
-Graduated treatment (n = 3)
Excluded (n = 51)
-Inclusion criteria not met (n = 28)
-Not Interested (n = 22)
-Withdrew (n = 1)
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Participant Characteristics 
Characteristics of Overall Sample  
 Participants (N = 51) were adults currently enrolled in substance use treatment at St. 
Christopher’s Addiction Wellness Center in Baton Rouge, LA. The overall sample was male 
(100%) and the majority was White (96.1%). Mean age was 31.1 (SD = 11.0) years. On average, 
participants reported smoking for 12.9 years (SD = 11.0), and most were daily smokers (90.2%). 
See Table 1 for baseline characteristics for the overall sample, participants who completed the 
baseline assessment only, and participants who completed the baseline assessment and one or 
more follow-ups. 
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Table 1. Participant Characteristics  
   
Characteristics 
Baseline  
(n = 35),  
M (SD) or % 
Past Baseline 
Completers  
(n = 16), 
M (SD) or % 
All Participants  
(N = 51), 
M (SD) or % 
Last use of any substance (days) 10.1 (9.6) 8.7 (10.4) 9.6 (9.8) 
Age of first substance use 13.2 (3.5) 11.9 (2.0) 12.7 (3.1) 
Number of treatment centers attended 1.4 (1.6) 1.9 (2.1) 1.6 (1.8) 
Longest period of abstinence 539.3 (831.9) 341.7 (527.6) 466.5 (733.0) 
CO monitor reading (ppm) 27.6 (15.2) 29.5 (13.6) 28.2 (14.6) 
Age 32.2 (10.4) 28.6 (12.4) 31.1 (11.0) 
Education (years)  13.3 (2.1) 13.7 (2.4) 13.4 (2.2) 
Annual household income 50,964.4 (39,310.4) 33,933.3 (38,246.4) 45,528.9 (39,382.7) 
Employment status (% unemployed) 42.9% 62.5% 49% 
Ethnicity (% white) 94.3% 100% 96.1% 
Cigarettes smoked per day 16.2 (8.5) 14.9 (7.2) 15.8 (8.1) 
How many serious quit attempts prior to STC 2.1 (3.2) 1.4 (1.8) 1.9 (2.9) 
Number of substance use disorders* 1.6 (1.0) 2.2 (0.8) 1.8 (1.0) 
Number of other psychological disorders  1.0 (0.8) 1.4 (0.8) 1.1 (0.8) 
FTND 4.9 (2.0) 4.1 (2.8) 4.7 (2.3) 
URICA  8.7 (3.4) 8.8 (3.9) 8.7 (3.5) 
SCQ-A Health Risks  7.2 (2.6) 8.2 (1.1) 7.5 (2.3) 
SCQ-A Negative Affect Reduction  6.2 (2.7) 5.2 (2.0) 5.9 (2.5) 
Note: M = Mean, SD = Standard Deviation  
* Denotes significance (p < 0.05) on demographic variables between participants who completed baseline 
assessments and those who completed baseline and one or more follow-ups. 
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Characteristics of Participants Included in Analyses for Aims 1, 2, and 3  
 Participants (N = 16) included in aims 1, 2, and 3 were all male (100%) and White 
(100%), and the mean age was 28.6 (SD = 12.4) years. On average, participants reported 
smoking for 12.7 years (SD = 13.3), and the majority of the sample identified as daily smokers 
(93.8%).  
Reliability of Measures 
 The URICA consisted of 32-items (28 were used in analyses) and had good internal 
reliability (α = 0.87). The two domains taken from the SCQ-A displayed good to excellent 
internal reliability. The SCQ-A Negative Affect Reduction domain consisted of 9-items and 
displayed excellent internal reliability (α = 0.95). The SCQ-A Health Risks domain consisted of 
4-items and displayed good internal reliability (α = 0.88). The FTND consisted of 6-items and 
displayed poor internal reliability (α = 0.58). Past research has found the FTND to have 
questionable internal reliability, which was anticipated in the current study. The URICA was 
used as the outcome measure in aim 1, the SCQ-A Health Risks domain was used as the outcome 
measure in aim 2, and the SCQ-A Negative Affect Reduction domain was used as the outcome 
measure in aim 3.  
Baseline Measures 
Overall Sample Baseline Measures 
 On the URICA, the mean readiness to change score was 8.7 (SD = 3.5). The URICA was 
transformed to a categorical variable to identify the prevalence of specific stages. Analyses 
indicated that in the overall sample, 35.4% of participants were in the precontemplation stage, 
33.3% of participants were in the contemplation stage, 29.2% were in the preparation (action) 
stage, and 2.1% were in the maintenance stage. On the SCQ-A Health Risks subscale the mean 
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score was 7.5 (SD = 2.3) and on the SCQ-A Negative Affect Reduction subscale the mean score 
was 5.9 (SD = 2.5).  
Participant Comparisons on Baseline Measures 
 Analyses were run to identify differences on baseline characteristics and measures 
between participants who completed the baseline assessment only (n = 35) and those who 
completed the baseline assessment and one or more follow-ups (n = 16).  
 Comparisons on Baseline Characteristics. The only significant difference on baseline 
characteristics was the number of substance use disorders present, reported by the psychiatrist or 
nurse practitioner, between those who completed the baseline assessment only (M = 1.6, SD = 
1.0) and those who completed the baseline assessment and one or more follow-ups (M = 2.2, SD 
= 0.8), t (41) = -2.02, p = 0.050. Participants who completed the baseline assessment and one or 
more follow-up assessments tended to have more substance use disorders.  
 URICA. On the URICA, there was no significant difference between participants who 
completed the baseline assessment only (M = 8.7, SD = 3.4) and participants who completed the 
baseline assessment and one or more follow-ups (M = 8.8, SD = 3.9), t (46) = -0.09, p = 0.926. 
The baseline assessment URICA readiness to change score was transformed to a categorical 
variable to examine prevalence of reported stage of change between participants who completed 
the baseline assessment only and participants who completed the baseline and one or more 
follow-ups. Analyses indicated among participants who completed the baseline assessment only, 
42.4% were in the precontemplation stage, 30.3% were in the contemplation stage, 24.2% were 
in the preparation (action) stage, and 3% were in the maintenance stage. Among participants who 
completed baseline and one or more follow-ups 20% were in the precontemplation stage, 40% 
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were in the contemplation stage, 40% were in the preparation (action) stage, and none were in 
the maintenance stage. 
 SCQ-A Health Risks. On the SCQ-A Health Risks subscale, there was no significant 
difference between participants who completed the baseline assessment only (M = 7.2, SD = 2.6) 
and participants who completed the baseline assessment and one or more follow-ups (M = 8.2, 
SD = 1.1), t (46.87) = -1.91, p = 0.062. 
 SCQ-A Negative Affect Reduction. On the SCQ-A Negative Affect Reduction subscale, 
there was no significant difference between the participants who completed the baseline 
assessment only (M = 6.2, SD = 2.7) and participants who completed the baseline assessment 
and one or more follow-ups (M = 5.2, SD = 2.0), t (47) = 1.20, p = 0.238. 
Correlations 
Baseline Correlations of Overall Sample 
 Education was negatively correlated with longest period of abstinence from substances (r 
= -0.33, p = 0.049) and positively correlated with age (r = 0.31, p = 0.037). Years smoking was 
positively correlated with age (r = 0.81, p = 0.000). Cigarettes smoked per day was positively 
correlated with CO reading (r = 0.61, p = 0.000), age (r = 0.31, p = 0.034), and years smoking (r 
= 0.46, p = 0.001). Number of substance use disorders present was positively correlated with age 
of first substance use (r = 0.34, p = 0.026) and negatively correlated with age (r = -0.34, p = 
0.024). The FTND was positively correlated with CO reading (r = 0.33, p = 0.022), age (r = 
0.35, p = 0.015), years smoking (r = 0.42, p = 0.003), and cigarettes smoked per day (r = 0.55, p 
= 0.000). The SCQ-A Health Risks subscale was positively correlated with number of substance 
use treatment centers attended (r = 0.37, p = 0.013), years smoking (r = 0.35, p = 0.016), and the 
URICA (r = 0.41, p = 0.005). The SCQ-A Negative Affect Reduction subscale was negatively 
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correlated with days since last use of any substances (r = -0.47, p = 0.002) and positively 
correlated with the FTND (r = 0.39, p = 0.006), the URICA (r = 0.36, p = 0.015), and the SCQ-A 
Health Risks subscale (r = 0.39, p = 0.007). See Table 2 for correlations of the overall sample. 
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Table 2. Correlations among baseline study variables for overall sample (N = 51) 
 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 
1. Last use of substance - - - - - - - - - - - - - - - 
2. Age of first use -0.12 - - - - - - - - - - - - - - 
3. # Treatment centers -0.09 -0.09 - - - - - - - - - - - - - 
4. Longest abstinence -0.15 0.04 0.06 - - - - - - - - - - - - 
5. CO  (ppm) a -0.29 -0.20 0.00 -0.07 - - - - - - - - - - - 
6. Age 0.20 0.03 0.01 0.20 -0.04 - - - - - - - - - - 
7. Education 0.29 -0.15 0.27 -0.33* -0.18 0.31* - - - - - - - - - 
8. Years smoking 0.17 -0.17 -0.07 0.16 0.09 0.81*** 0.21 - - - - - - - - 
9. CPD b -0.16 -0.23 -0.20 0.05 0.61*** 0.31* -0.02 0.46** - - - - - - - 
10. Quit attempts prior -0.12 0.00 0.18 0.33 0.08 -0.04 0.04 -0.07 0.10 - - - - - - 
11. SUD c -0.16 0.34* -0.03 -0.16 -0.15 -0.34* 0.02 -0.27 -0.26 -0.19 - - - - - 
12. Psychological disorders -0.18 -0.01 -0.14 0.01 0.02 -0.15 -0.11 -0.10 -0.03 -0.03 0.27 - - - - 
13. FTND -0.21 -0.04 -0.05 0.14 0.33* 0.35* -0.18 0.42** 0.55*** 0.11 -0.25 -0.16 - - - 
14. URICA -0.11 0.09 0.20 0.13 0.20 -0.04 -0.24 0.03 0.03 -0.01 0.01 -0.19 0.14 - - 
15. SCQ-A Health Risks -0.05 -0.09 0.37* 0.15 0.27 0.26 0.14 0.35* 0.07 0.17 0.08 0.05 0.21 0.41** - 
16. SCQ-A Negative Affect -0.47** 0.01 0.16 0.14 0.22 0.09 -0.21 0.08 0.12 0.10 0.01 -0.07 0.39** 0.36* 0.39** 
a CO (ppm) = Carbon monoxide (parts per million) 
b CPD = Cigarettes per day 
c SUD = Substance use disorders 
*p < 0.05; **p < 0.01, ***p < 0.001 
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Baseline Correlations of Participants Included in Analyses for Aims 1, 2, and 3  
 Education was negatively correlated with CO reading (r = -0.50, p = 0.050.) Years 
smoking was positively correlated with age (r = 0.94, p = 0.000). Cigarettes smoked per day was 
positively correlated with CO reading (r = 0.52, p = 0.047), age (r = 0.62, p = 0.013), and years 
smoking (r = 0.69, p = 0.004). Number of smoking quit attempts prior to entering St. 
Christopher’s was positively correlated with longest period of abstinence from substances  (r = 
0.58, p = 0.048). Number of psychological disorders was negatively correlated with age (r = -
0.59, p = 0.026) and education (r = -0.67, p = 0.008). The FTND was positively correlated with 
CO reading (r = 0.65, p = 0.009), years smoking (r = 0.62, p = 0.013), and cigarettes smoked per 
day (r = 0.86, p = 0.000). The SCQ-A Health Risks subscale was positively correlated with the 
URICA (r = 0.56, p = 0.026). The SCQ-A Negative Affect Reduction subscale was negatively 
correlated with days since last use of any substances (r = -0.58, p = 0.023) and positively 
correlated with CO reading (r = 0.67, p = 0.005), cigarettes smoked per day (r = 0.59, p = 0.021), 
and the FTND (r = 0.57, p = 0.026). See Table 3 for correlations of the participants included in 
analyses for aims 1, 2, and 3. 
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Table 3. Correlations among baseline study variables for main analyses sample (n = 16) 
 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 
1. Last use of substance - - - - - - - - - - - - - - - 
2. Age of first use -0.05 - - - - - - - - - - - - - - 
3. # Treatment centers 0.09 0.12 - - - - - - - - - - - - - 
4. Longest abstinence -0.05 0.14 0.28 - - - - - - - - - - - - 
5. CO reading a -0.44 -0.21 -0.03 0.05 - - - - - - - - - - - 
6. Age -0.07 0.29 -0.14 0.31 -0.04 - - - - - - - - - - 
7. Education 0.29 0.27 0.31 0.39 -0.50* 0.42 - - - - - - - - - 
8. Years smoking -0.04 0.16 -0.11 0.44 0.15 0.94*** 0.25 - - - - - - - - 
9. CPD b -0.35 0.00 -0.07 -0.08 0.52* 0.62* 0.01 0.69** - - - - - - - 
10. Quit attempts prior -0.30 0.03 0.01 0.58* 0.47 -0.04 -0.08 0.04 0.05 - - - - - - 
11. SUD c 0.05 0.03 0.15 -0.02 -0.27 -0.42 0.02 -0.39 -0.23 -0.19 - - - - - 
12. Psychological disorders -0.11 -0.17 -0.17 -0.45 0.10 -0.59* -0.67** -0.42 -0.25 -0.24 0.47 - - - - 
13. FTND -0.41 -0.32 0.02 -0.12 0.65** 0.50 -0.09 0.62* 0.86*** 0.25 -0.45 -0.26 - - - 
14. URICA 0.20 -0.09 0.04 0.19 0.28 0.09 -0.10 0.13 0.06 -0.09 -0.22 -0.13 0.03 - - 
15. SCQ-A Health Risks 0.25 0.32 0.17 0.31 0.21 0.20 0.19 0.15 0.13 0.23 -0.04 -0.51 0.12 0.56* - 
16. SCQ-A Negative Affect -0.58* 0.00 -0.03 0.05 0.67** 0.16 -0.08 0.17 0.59* 0.46 0.10 -0.16 0.57* 0.08 0.21 
a CO (ppm) = Carbon monoxide (parts per million) 
b CPD = Cigarettes per day 
c SUD = Substance use disorders 
*p < 0.05; **p < 0.01, ***p < 0.001 
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Missing Data 
 If a participant was unable to be reached within the time frame window for a follow-up 
assessment, due to participant or researcher availability, a researcher attempted to contact him at 
the next time point. As a result, there were several participants who completed the 60-day 
follow-up who were missing data from the 30-day visit and several participants who completed 
the 30-day follow-up who were missing data from the 60-day follow-up. Of these participants 
who completed one or more follow-ups, 13 completed the 30-day follow-up, 9 completed the 60-
day follow-up, and 3 completed the 90-day follow-up. 16 participants were identified as 
completing the baseline assessment and one or more follow-up assessments. Of these 16 
participants, there was one who did not respond to items on the baseline URICA and one who 
did not respond to items on the baseline SCQ-A Health Risks subscale. However, both of these 
participants completed all of the 30- and 60-day follow-up measures and were included in the 
main outcome analyses. Missing value analyses were conducted to identify the percentage of 
missing data across time points for scores on the URICA, SCQ-A Health Risks subscale, and the 
SCQ-A Negative Affect Reduction subscale. On the URICA, 6.3% (n = 1) of data was missing at 
baseline, 18.8% (n = 3) of data was missing at 30-day follow-up, and 43.8% (n = 7) of data was 
missing at the 60-day follow-up. On the SCQ-A Health Risks subscale, 6.3% (n = 1) of data was 
missing at baseline, 18.8% (n = 3) of data was missing at 30-day follow-up, and 43.8% (n = 7) of 
data was missing at the 60-day follow-up. On the SCQ-A Negative Affect Reduction subscale, 
0% (n = 0) of data was missing at baseline, 18.8% (n = 3) of data was missing at 30-day follow-
up, and 43.8% (n = 7) of data was missing at the 60-day follow-up. At baseline and 30- and 60-
day follow-up, mean substitution was implemented for scores on outcome variables. For tests of 
the 3 main hypotheses, data from the 90-day follow-up were excluded, as mean substitution was 
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not appropriate for such a small sample size. Mean substitution was implemented to handle 
missing data only on outcome variables (e.g., URICA, SCQ-A Health Risks subscale, and SCQ-
A Negative Affect Reduction subscale). While mean substitution does have limitations, it is a 
conservative procedure for handling missing data (Tabachnick & Fidell, 2013). Mean 
substitution was implemented to reduce the risk of a Type I error occurring. For the URICA, 
mean substitution was calculated for the Readiness to Change score, a continuous variable. For 
the SCQ-A mean substitution was used for the final scores on each subscale (e.g., the mean of 
each subscale). See Table 4 for scores on outcome variables with mean substitution 
implemented. 
Table 4. Scores on outcome variables with mean substitution implemented (n = 16) 
 Baseline  
M (SD) 
30-day follow-up  
M (SD) 
60-day follow-up  
M (SD) 
URICA  8.8 (3.8) 9.0 (2.6) 8.6 (2.2) 
SCQ-A Health Risks  8.2 (1.0) 8.1 (1.4) 6.4 (2.2) 
SCQ-A Negative Affect  5.2 (2.0) 5.5 (1.8) 3.8 (1.9) 
Note: M = Mean, SD = Standard Deviation  
Aim 1 
Repeated Measures ANOVA  
 A repeated measures ANOVA was conducted to determine differences on URICA scores 
across assessments. Bonferonni correction was applied to post hoc analyses to control for the 
increased probability of a Type 1 error occurring. 
 Mauchly’s Test of Sphericity revealed the assumption of sphericity had not been violated, 
χ2 (2) = 5.56, p = 0.062. A repeated measures ANOVA revealed that URICA scores did not 
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differ significantly between time points F (2, 30) = 0.09, p = 0.912. See Table 4 for scores on the 
URICA across time points. 
Aim 2 
Repeated Measures ANOVA 
 A repeated measures ANOVA was conducted to determine differences in SCQ-A Health 
Risks subscale scores across assessments. Bonferonni correction was applied to post hoc 
analyses to control for the increased probability of a Type 1 error occurring. 
 Mauchly’s Test of Sphericity revealed the assumption of sphericity had not been violated, 
χ2 (2) = 4.55, p = 0.103. A repeated measures ANOVA revealed that SCQ-A Health Risks 
subscale scores differed significantly between time points F (2, 30) = 5.68, p = 0.008, ηp2 = 0.28. 
Post hoc tests using Bonferroni correction detected no significant difference between baseline (M 
= 8.2, SD = 1.0) and 30-day follow-up (M = 8.1, SD = 1.4) (p = 1.000). There were no significant 
differences between baseline (M = 8.2, SD = 1.0) and 60-day follow-up (M = 6.4, SD = 2.2) (p = 
0.068). However, there was a significant difference between 30-day follow-up (M = 8.1, SD = 
1.4) and 60-day follow-up (M = 6.4, SD = 2.2) (p = 0.050). See Table 4 for scores on the SCQ-A 
Health Risks subscale across time points. 
Aim 3 
Repeated Measures ANOVA 
 A repeated measures ANOVA was conducted to determine differences in SCQ-A 
Negative Affect Reduction subscale scores across assessments. Bonferonni correction was 
applied to post hoc analyses to control for the increased probability of a Type 1 error occurring. 
 Mauchly’s Test of Sphericity revealed the assumption of sphericity had not been violated, 
χ2 (2) = 1.61, p = 0.446. A repeated measures ANOVA revealed that SCQ-A Negative Affect 
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Reduction subscale scores differed significantly between time points F (2, 30) = 6.70, p = 0.004, 
ηp2 = 0.31. Post hoc tests using Bonferroni correction detected no significant difference between 
baseline (M = 5.2, SD = 2.0) and 30-day follow-up (M = 5.5, SD = 1.8) (p = 1.000). There was a 
significant differences between baseline (M = 5.2, SD = 2.0) and 60-day follow-up (M = 3.8, SD 
= 1.9) (p = 0.018) and a significant difference between 30-day follow-up (M = 5.5, SD = 1.8) and 
60-day follow-up (M = 3.8, SD = 1.9) (p = 0.030). See Table 4 for scores on the SCQ-A 
Negative Affect Reduction subscale across time points. 
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DISCUSSION 
 The purpose of the current study was to determine whether readiness to change, health 
risk smoking expectancies and negative affect reduction smoking expectancies differed between 
baseline assessment, 30-day follow-up, and 60-day follow-up for smokers in substance use 
treatment. In relation to aim 1, it was hypothesized that readiness to quit smoking would increase 
over time as smokers in substance use treatment learned new coping skills and information about 
the negative health risks of other substances. It was hypothesized that this information would 
generalize to smoking behavior, and thereby increase readiness to quit smoking. In relation to 
aim 2, it was hypothesized that health risk smoking expectancies would increase over time as 
smokers in substance use treatment learned health-oriented information and information about 
the negative health effects of substance abuse. The information learned in treatment about the 
negative health effects of other substances was hypothesized to generalize to smoking. In relation 
to aim 3, it was hypothesized that negative affect reduction smoking expectancies would 
decrease over time due to smokers in substance use treatment learning other coping skills to 
manage negative affect other than smoking. Analyses indicated changes in readiness to quit 
smoking were not significantly different across assessments. This finding was contrary to the 
hypothesis that readiness to quit smoking would increase with time spent in substance use 
treatment. There was a significant change over time in expectancies for health risks, but it was in 
the opposite direction of that hypothesized. That is, health risk expectancies significantly 
decreased over time in treatment. Lastly, there was a significant change over time in negative 
affect reduction expectancies occurring in the hypothesized direction with decreased scores 
identified at the 60-day assessment.  
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Baseline Characteristics and Measures 
Overall Sample 
 In the overall sample, a majority of participants were identified as being in either the 
precontemplation or contemplation stage of change on the URICA upon entry to St. 
Christopher’s. There are several possible explanations as to why smokers entering substance use 
treatment may not be interested or ambivalent towards quitting smoking. In the overall sample, 
continuous baseline URICA scores were positively correlated with health risk smoking 
expectancies, indicating that participants in earlier stages of change tended to have lower health 
risk smoking expectancies. Consistent with the current findings, past research has found 
increased value of health to be predictive of successful cessation and health-related beliefs about 
the consequences of smoking to be a strong predictor of motivation to quit smoking (Copeland et 
al., 1995; McCaul et al., 2006; Rose et al., 1996). Interestingly, in the overall sample, continuous 
baseline URICA scores were positively correlated with negative affect reduction smoking 
expectancies, indicating that participants in earlier stages of changed tended to have lower 
expectancies for smoking to reduce negative affect. Higher negative affect reduction and 
negative reinforcement expectancies have been found to be predictive of post-cessation smoking 
outcomes (Copeland et al., 1995; Wetter et al., 1994). Findings from the overall sample at 
baseline indicate that it might be beneficial to provide stage-matched intervention (e.g., 
consciousness raising) for precontemplator and contemplator smokers, who were identified to 
have lower health risk expectancies upon entering substance use treatment. The association 
between lower negative affect reduction expectancies and earlier stages of change may also 
provide opportunity for intervention. Smokers in early stages of change who do not have high 
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expectancies for smoking to reduce negative affect may be more receptive to learning coping 
skills other than smoking to manage negative affect.  
Participant Comparisons on Baseline Measures 
 A significant number of participants who completed the baseline assessment only were 
excluded from analyses for aims 1, 2, and 3. Comparison analyses between participants who 
completed the baseline assessment only and participants who completed the baseline assessment 
and one or more follow-ups revealed one significant difference. Participants who completed the 
baseline assessment and one or more follow-ups were identified as having significantly more 
substance use disorders compared to participants who only completed baseline. This difference 
in groups is somewhat intuitive, as it would be expected that those with a greater number of 
substance use disorders would likely stay longer in substance use treatment. No other significant 
differences were found between participants who completed the baseline assessment only and 
those who completed baseline and one or more follow-up assessments on the baseline URICA, 
SCQ-A Health Risks subscale, and SCQ-A Negative Affect Reduction subscale. Comparison 
analyses provided evidence that those who completed the baseline assessment only and those 
who completed the baseline assessment and one or more follow-up assessments were not 
significantly different on baseline measures.   
Main Outcomes 
Aim 1 
 It was hypothesized in aim 1 that readiness to quit smoking would significantly increase 
over time as an indirect effect of being in a long-term multimodal substance use treatment center. 
However, this hypothesis was not supported as no significant difference was identified in 
readiness to quit scores across assessments. At St. Christopher’s, patients learn behavioral and 
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cognitive coping strategies to manage distress/ prevent relapse and learn about the negative 
health consequences of substance abuse through psychoeducation. The apparent incongruity 
between readiness to change substance use and readiness to change smoking behavior may be 
explained by the substance use treatment context and culture. Individuals in early substance use 
recovery report receiving advice to postpone smoking cessation attempts from a variety of 
sources, including treatment center staff (Richter et al., 2002). It is therefore likely that even 
smokers who are currently contemplating a cessation attempt would not progress in readiness to 
quit smoking when they are being told cessation is inadvisable or even detrimental to their 
substance use recovery. In past research, investigators have concluded that cessation 
interventions for smokers in substance use treatment should include evidence-based information 
regarding the myriad benefits of quitting smoking (Hendricks et al., 2014). The provision of this 
information would be consistent with strategies such as ‘consciousness raising’ that are 
suggested by J. O. Prochaska and DiClemente (1982) as stage-matched processes of change for 
assisting precontemplators and contemplators to progress to the next stage of readiness or 
motivation toward addictive behavior change. Within the current study, a majority of participants 
who completed the baseline assessment and one or more follow-up assessments were in the 
precontemplation or contemplation stage of change at baseline. Implementing consciousness 
raising interventions, such as providing information about the causes, consequences, and 
treatments related to smoking, for smokers in early stages of substance use treatment may be 
beneficial for increasing readiness to quit smoking among this population (J. O. Prochaska et al., 
2015). Of course, there is also an extensive literature within addictive behavior change in which 
motivation for change is addressed directly via motivational enhancement strategies and brief 
motivational interventions (BMIs) in which the patient’s ambivalence toward change is expected 
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and acknowledged, and the patient is provided with treatment information only upon request 
(Miller & Rose, 2009). Research has shown that even providing brief advice about quitting 
smoking increases motivation to quit among smokers in substance abuse treatment (Rohsenow et 
al., 2014). In addition, pre-cessation motivational enhancement interventions have been found to 
be useful for increasing interest in cessation programs in the context of substance abuse 
treatment (Guydish et al., 2016). While interventions targeting motivation to quit smoking have 
been found to be successful, most are implemented in the early stages of treatment and 
motivation to quit is assessed in a similar time frame. The purpose of the current study was to 
determine if readiness to quit smoking was malleable to attendance in long-term substance use 
treatment, which was not supported. Interventions, such as BMIs or brief advice, may be 
necessary to increase readiness to quit for smokers in substance use treatment. Future research 
should focus efforts on tailoring proactive interventions to increase motivation to quit among 
smokers in substance use treatment.  
Aim 2 
 In relation to aim 2, it was hypothesized that smoking expectancies for health risks would 
increase over time in substance use treatment. This hypothesis was based on the rationale that 
psychoeducational components of substance use treatment programs regarding health risks 
associated with substance use would generalize to patients’ smoking behavior as well, and this 
would be reflected in increased health risk smoking expectancies over time. Contrary to 
prediction, smoking expectancies for health risks significantly decreased over time in treatment.  
The significant decrease was detected from the 30-day follow-up assessment to the 60-day 
follow-up assessment. This unexpected finding may again be due to a lack of information, or 
misinformation, that smokers receive in substance use treatment regarding the significant health 
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risks associated with continued smoking and the substantial health improvements associated with 
cessation. It is established in the literature that smokers with substance use comorbidities are 
more likely to die from smoking-related illness than alcohol use and are at an increased risk for 
mortality (Bandiera et al., 2015; Hser et al., 1994; Hurt et al., 1996). Although research on the 
negative health consequences of smoking for those with substance use disorders has been 
documented, this information may not be widely disseminated to staff or patients in substance 
use treatment centers. A recent meta-analysis determined that among mental health professionals 
(e.g., nurses, psychiatrists, and clinical psychologists) treating mental illness and substance use 
disorders, almost half reported negative attitudes towards patients quitting smoking and 
acceptance towards patients continuing to smoke (Sheals, Tombor, McNeill, & Shahab, 2016). 
Interestingly, staff in substance use treatment centers have been found to be supportive of 
cessation for patients as a result of health concerns (Richter et al., 2012). However, support of 
cessation for patients due to health concerns among staff was partly accounted for by the belief 
that smoking would exacerbate physiological conditions due to the use of other substances 
(Richter et al., 2012). This provides further support of a potential gap in the information 
disseminated to staff in substance use treatment centers regarding the significance of health 
consequences of smoking within this population.  
A potential avenue for future research is the development of interventions aimed at 
educating mental health professionals and patients about the health consequences of smoking for 
those in substance use treatment. In conclusion, it may be necessary to provide psychoeducation 
regarding the health risks of smoking in substance use treatment to proactively address 
misconceptions about the health consequences of smoking in this context. The decrease in health 
risk expectancies over time offers support that smoking cessation services should be offered at 
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treatment entry, or within the first 30 days, of substance use treatment as this is when health risk 
expectancies were found to be the highest. Of note, the current study did not include a proactive 
strategy in which smoking expectancies for health risks were specifically targeted for change. In 
previous studies in which expectancies have been changed, they were targeted by a manipulation 
in which information was presented to challenge the belief (e.g., there are effective alternatives 
to smoking for reducing negative affect) or to augment existing beliefs (e.g., personalizing 
smoking-related health risk information) to reinforce or increase health risk expectancies 
(Copeland & Brandon, 2000). Future research should attempt to target the manipulation of health 
risk smoking expectancies among smokers in substance use treatment.  
Aim 3 
 In relation to Aim 3, it was hypothesized that negative affect reduction expectancies 
would decrease over time in substance use treatment, as patients acquire alternative skills to 
manage their negative moods. This hypothesis was supported, as there was a significant change 
in negative affect reduction expectancies as a function of time or experience in substance use 
treatment with lowest scores reported at the 60-day follow-up. It was anticipated that knowledge 
from substance use treatment would generalize from substance use to smoking and that 
knowledge would be sufficient (albeit indirect) to modify existing smoking expectancies for 
negative affect reduction. The findings indicate that generalization did occur and was robust 
enough to modify expectancies. St. Christopher’s multimodal program utilizes evidence-based 
treatments, including dialectical behavior therapy skills and acceptance commitment therapy as 
components of group and individual therapy (STC, 2016). A core component of both these 
evidence-based treatments is mindfulness (Luoma, Hayes, & Walser, 2007; McKay, Wood, & 
Brantley, 2019). Research has shown mindful attention to be negatively associated with negative 
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affect among smokers (Paulus, Langdon, Wetter, & Zvolensky, 2018). Among those in cessation 
programs, mindfulness has been associated with decreased expectancies of smoking to improve 
mood (Spears et al., 2019). Although St. Christopher’s program is not entirely centered on the 
use of mindfulness-based interventions in the treatment of substance use disorders, exposure to 
such interventions may have generalized to smoking behavior and negative affect reduction 
smoking expectancies. Findings suggest that it may be beneficial to provide cessation services 
later in treatment when patients have established other coping strategies to manage negative 
affect other than smoking. While treatment at St. Christopher’s incorporates interventions with 
mindfulness components, future research should identify which specific coping skills to manage 
negative affect developed in substance use treatment are linked to decreases in negative affect 
reduction smoking expectancies. It may be the case that negative affect reduction smoking 
expectancies can also be directly addressed and challenged in the context of substance use 
treatment, in order to be significantly modified. For example, this might entail teaching patients 
effective, alternate, concrete skills to manage negative mood (e.g., deep breathing, relaxation) 
without resorting to smoking. Another strategy might be to challenge the validity of the belief by 
developing competing cognitions, such as smoking is only a temporary fix for negative mood 
and precludes the smoker from addressing the source of negative affect and potentially resolving 
it. In previous studies, efforts to then personalize this information have been effective in 
changing expectancies in the desired direction (Copeland & Brandon, 2000). Future research is 
needed to determine if negative affect reduction expectancies can be challenged earlier on in 
substance use treatment prior to 60 days.  
Limitations 
 There were several notable limitations to the current study, such that the current findings 
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should be interpreted with caution. First, the study was significantly underpowered. A power 
analysis indicated that a sample of at least 46 participants completing all four assessments was 
required to detect meaningful differences over time if they occurred. While the required sample 
size was not met, the most conservative methods of handling missing data and performing 
statistical analyses were implemented to prevent a Type I error occurrence. Out of the patients 
admitted to St. Christopher’s during recruitment for the current study, only 38.6% completed the 
baseline assessment and only 12.1% completed the baseline assessment and one or more follow-
ups. Mean substitution was implemented for 22.9% of data used in aims 1 and 2 and 20.8% of 
data used in aim 3. The small sample used in aims 1, 2, and 3 was highly biased based on self-
selection to stay in treatment and is most likely unrepresentative of smokers in substance use 
treatment. It was identified that participants who completed the baseline assessment only and 
those who completed the baseline and one or more follow-ups did not significantly differ on 
baseline assessments and measures other than the number of substance use disorders present. It 
was hypothesized that coping skills learned in substance use treatment would indirectly 
generalize from substance use to smoking and this generalization would modify readiness to quit 
smoking and negative affect reduction smoking expectancies. While negative affect reduction 
smoking expectancies did decrease, potentially due to the acquisition of coping skills learned in 
substance use treatment, the current study did not include a measure of coping skills. Future 
research examining changes in readiness to quit smoking and negative affect reduction smoking 
expectancies in the context of substance use treatment should include a measure of coping skills, 
specifically, cognitive coping skills.  
 Overall changes to St. Christopher’s program contributed to difficulties with baseline and 
follow-up data collection. Strategies were implemented in an effort to overcome these 
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difficulties. Prior to beginning study recruitment, a presentation was provided to the staff at St. 
Christopher’s, giving an overview of the study in an effort to build staff “buy-in” to assist with 
data collection. In the early phases of study recruitment, several staff who had initially agreed to 
assist in the collection of data were no longer working at St. Christopher’s or were working in 
other positions within the facility. The reduction in staff assistance led to researchers spending 
increased time attempting to locate participants for baseline assessments and follow-ups. There 
was also a turnover in the retention of researchers who were recruiting participants and 
administering baseline measures. The loss of researchers who were available to recruit and 
administer baseline assessments led to a number of patients being ineligible to participate due to 
seven days passing following their admittance to St. Christopher’s. As a result, other researchers 
assisting with data collection were reassigned from collecting follow-up assessments to help with 
baseline data collection. In the early phases of data collection, the treatment center changed 
ownership and the head admissions coordinator resigned. The head admissions coordinator 
would actively recruit patients and their families to commit to long-term treatment. Following his 
resignation, a number of patients were found to be discharging treatment or transitioning to a 
lower level of care earlier than usual. 
 Regarding issues with initial baseline recruitment, a number of patients reported not 
being interested for several reasons. Throughout data collection, several patients reported 
disinterest in participation due to the lack of incentives for the time it took to complete the four 
assessments. Unfortunately, the inclusion of incentives posed ethical problems as participants 
had to be smokers in order to be eligible for the study. Incentivizing participation could have 
potentially led to patients at St. Christopher’s to begin smoking in order to receive incentives for 
participation. During the middle phase of baseline data collection, it was determined that patients 
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were reporting disinterest due to one participant advising others not to participate. The 
participant was informing others that he believed the proposed sample size addressed in the 
consent form was not adequately powered. The researcher collecting baseline data with this 
participant discussed how the proposed sample size was determined. Another researcher met 
with this participant at a later date to address that the sample size proposed in the consent form 
was sufficient and to please refrain from discussing the study with other patients. Furthermore, to 
circumvent this problem, the researcher collecting baseline data had staff at St. Christopher’s 
bring patients to the office where data was collected. This change in procedure was done in lieu 
of the researcher approaching patients in the milieu where they could be swayed by the opinions 
of others. This seemed to reduce the influence of patients deterring potential participants. The 
EMR charting system posed a problem in identifying newly admitted patients. The EMR 
charting system labeled potential admits to St. Christopher’s the same as newly admitted 
patients. As a result, there were several instances where the first author contacted one of the 
study recruitment researchers to meet with a potential participant only to find out that the patient 
had decided against coming to treatment. One of the researchers was actively working at St. 
Christopher’s and became a point of contact to identify if a patient admitted into treatment and 
could be contacted for recruitment.  
 The collection of follow-up assessments became significantly more difficult as data 
collection proceeded. As mentioned earlier, the head admissions counselor and several staff 
resigned from their positions throughout the early to middle stages of data collection and there 
was a transition in ownership. Several of the staff who had initially agreed to assist researchers 
with collecting follow-up data resigned or transitioned to other roles within the facility. 
Researchers significantly increased the number of days and times they would attempt to follow-
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up with participants, which was not always successful. Identifying when a participant was 
transitioning from one level of care to the next or discharging from the program was also 
problematic for collecting follow-ups. This information was not available within the EMR 
system. To address this problem, the researcher conducting follow-ups would call counselors or 
staff days prior to the anticipated follow-up date to check the patient’s discharge/transition date 
in an attempt to follow-up prior to discharge/ transition.  
 Finally, there were changes made to the medical and psychological intake evaluation 
format and a transition to a new EMR charting system, which resulted in difficulty in collecting 
some information for the Substance Use and Mental Health Form. The old EMR charting system 
included a psychosocial assessment form that was used to develop items on the Substance Use 
and Mental Health Form used in the current study. The new EMR charting system did not use 
this same psychosocial assessment form. Information pertaining to previous mental health 
treatment (other than substance use treatment) was not collected from the EMR charting system. 
Within the psychiatrist and nurse practitioner notes in the EMR charting system, the explanation 
for prescription of certain medications was not always clear. A number of medications have off-
label psychiatric uses, which made it unclear as to the reason for a prescription if not stated 
explicitly. For example, gabapentin is prescribed as an adjunctive medication for alcohol use 
disorder (Mason, Quello, & Shadan, 2018), yet it is also prescribed for seizures (Chadwick et al., 
1998) and diabetic neuropathy (Moore, Wiffen, Derry, & Rice, 2014). Due to the variability in 
the explicit identification of the purpose of prescribed medication, this information was not 
collected.  
Conclusion 
 The results of the current study provide some insight into when smokers in substance use 
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treatment may be most receptive to quitting smoking. It was determined that readiness to quit 
smoking did not differ significantly by assessment, while negative affect reduction and health 
risk smoking expectancies were both found to significantly decrease at the 60-day follow-up. 
Results may seem contradictory as decreased negative affect reduction expectancies and 
increased health risk expectancies have been found to be predictive of quit attempts and 
successful cessation (Copeland et al., 1995). It may be beneficial to incorporate a manipulation 
to challenge the beliefs or to augment existing beliefs related to health risk expectancies early on 
in substance use treatment. Coping skills learned in substance use treatment may generalize to 
smoking behavior and reduce negative affect reduction smoking expectancies as a patient 
progresses through treatment. It may be especially important to include “pre-cessation readiness” 
or motivational enhancement interventions to increase readiness to quit, which have been found 
to be effective in prior literature (Guydish et al., 2016). Smokers in substance use treatment may 
need more comprehensive multicomponent cessation interventions to elicit change. In 
conclusion, it may be beneficial to provide cessation services between 30 and 60 days after 
entering substance use treatment when there has been an opportunity to augment health risk 
expectancies, provide pre-cessation motivational enhancement, and develop generalizable coping 
skills to manage negative affect. Future studies of this type should address issues of external 
validity and determine whether similar results are found in an adequately powered study, and 
whether similar results would be obtained with a population with diverse demographics, as the 
current study included only white males of a similar sociodemographic. Readiness to change and 
smoking outcome expectancies are important factors in determining the optimal timing of 
smoking cessation for smokers in substance use treatment, and further research is needed to 
understand the role of these constructs within this context.    
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APPENDIX A. CONSENT FORM 
 
Study Title:           Readiness to Change and Smoking Expectancies Among Adult Male Substance 
Users Currently in Substance Use Treatment 
 
Study Purpose 
and Procedure:  The purpose of this research project is to identify changes in smoking 
expectancies and readiness to quit smoking among adult males in substance use 
treatment. 
  
 The study requires that you complete several surveys at different times, 
including questionnaires regarding your use of cigarettes and other nicotine 
products, expectancies related to smoking, and readiness to quit smoking as 
well as a breathalyzer to determine current smoking. Additionally, information 
from your St. Christopher’s chart will be used to gather pertinent information 
regarding current and past psychological/medical history. 
 
Risks/Discomforts:  Participation in the study is not known to cause any physical or psychological 
risk or discomfort. Confidentiality is protected through use of a secured office 
and locked filing cabinet where all completed study materials will be stored. 
While every effort is being made to preserve confidentiality, there is always a 
remote possibility that thieves could obtain your data. Again, this is very unlikely 
given the multiple steps taken to assure that completed study measures kept 
protected. 
 
Benefits:              You will be contributing to our knowledge regarding smoking behavior among 
those in substance use treatment.  
 
Alternatives:   There are not alternatives for discontinuing participation. If you would like 
resources regarding smoking cessation a list of referrals will be provided, but we 
cannot attest to their efficacy. 
 
Contact:            Amy L. Copeland, Ph.D., M.P., the Principal Investigator, can be reached at 
copelan@lsu.edu. The Co-Investigator, Aaron Waters, M.A., can be reached at 
awater7@lsu.edu 
 
Performance Sites: St. Christopher’s Addiction Wellness Center 
                                   
Number of Participants:  The maximum number of participants we plan to enroll is 200. 
 
Subjects:  
Inclusion:    In order to participate in the study, participants must be 1) currently admitted  
   at St. Christopher’s, 2) be ≥ 18 years of age at the initial study visit, 3) be a  
   current smoker (e.g., report at least weekly smoking and provide an expired  
   carbon monoxide monitor reading of 8 > parts per million), 4) not mandated by  
   court system to attend substance use treatment, and 5) demonstrate a 7th  
   grade reading level or higher. 
Exclusion: Participants will be excluded if any of the above criteria are not met. 
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Privacy: Results of this study may be published, but no names or identifying information 
will be included in the publication. All personal information obtained in this 
study will be kept confidential. Your responses will be labeled only with a study 
identification number within an electronic database.  
 
Financial Information:  There is no financial compensation for participation in this study. 
 
Right to Refuse: Participation in this study is voluntary, and you may withdraw from the study at 
any time without prejudicing your future relations with St. Christopher’s 
Addiction Wellness Center.  
  
Unforeseeable Risks:    As with any study, confidentiality is a concern, however, confidentiality risk is 
unlikely given the steps we have taken to ensure that participant identifying 
information is kept confidential. Confidentiality is protected using locked filing 
cabinets in secured rooms at Louisiana State University. Additionally, we have 
obtained a Certificate of Confidentiality through the National Institutes of 
Health.  
 
Study-related illness  
or injury: Participants are instructed to seek necessary medical care from their physician 
and contact the Principal Investigator, Dr. Amy Copeland (copelan@lsu.edu) in 
the event of a study-related illness or injury. 
 
New Findings:   Any significant new findings developed from the study data or independent 
sources during the course of research which may influence your willingness to 
continue in the study will be explained to you. 
 
Withdrawal:    Participants may withdraw from the study at any time.  
               
Removal:   Obvious disruption, harm or threat of harm to other study participants or 
members of the research team will conclude in participant removal from the 
study. Additionally, if a participant leaves treatment at St. Christopher’s they 
will be removed.   
 
Certificate of  
Confidentiality: To help us protect your privacy, we have obtained a Certificate of Confidentiality 
from the National Institutes of Health. With this Certificate, the researchers 
cannot be forced to disclose information that may identify you, even by a court 
subpoena, in any federal, state, or local civil, criminal, administrative, legislative, 
or other proceedings. The researchers will use the Certificate to resist any 
demands for information that would identify you, except as explained below. 
The Certificate cannot be used to resist a demand for information from 
personnel of the United States Government that is used for auditing or 
evaluation of federally funded projects or for information that must be 
disclosed in order to meet the requirements of the federal Food and Drug 
Administration (FDA). 
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You should understand that a Certificate of Confidentiality does not prevent you 
or a member of your family from voluntarily releasing information about 
yourself or your involvement in this research. If an insurer, employer, or other 
person obtains your written consent to receive research information, then the 
researchers may not use the Certificate to withhold that information. 
The Certificate of Confidentiality does not prevent the researchers from 
disclosing voluntarily, without your consent, information that would identify you 
as a participant in the research project under the following circumstances: 
reporting of child abuse and intent to hurt self or others.  
 
Signatures:  “The study has been discussed with me and all my questions have been 
answered. I may direct additional questions regarding study specifics to the 
investigators. For injury or illness, call your physician, or the Student Health 
Center if you are an LSU student. If I have questions about subject’s rights or 
other concerns, I can contact Dennis Landin, Chairman, LSU Institutional Review 
Board, (225) 578-8692, irb@lsu.edu, or www.lsu.edu/research. I agree to 
participate in the study described above and acknowledge the researcher’s 
obligation to provide me with a copy of this consent form if signed by me.” 
 
 
Subject Signature: ____________________________ Date: _________________ 
 
 
Illiterate subjects:  When ANY subjects are likely to be illiterate, the "reader statement" and  
   signature line below are included.) 
 
   “The study subject has indicated to me that he/she is unable to read. I certify  
   that I read this consent form to the subject and explained by completing the  
   signature line above, the subject agreed to participate.” 
 
 
Signature of Reader: _____________________________ Date: _______________   
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For research involving the collection of identifiable private information or identifiable 
biospecimens one of the following must be listed on the consent form:  
 
Identifiers might be removed from the identifiable private information or identifiable 
biospecimens. After removal, the information or biospecimens may be used for future research 
studies or distributed to another investigator for future research studies without additional 
informed consent.  
 
 
Yes, I give permission________________________________________________  
Signature  
 
 
No, I do not give permission___________________________________________ 
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APPENDIX B. HIPAA AGREEMENT FORM  
 
Authorization to Use or Disclose (Release) Health Information that Identifies You for a Research 
Study 
 
If you sign this document, you give permission to St. Christopher’s Addiction Wellness Center (St. 
Christopher’s) to use or disclose (release) your health information that identifies you for the research 
study described here:  
 
 The current study titled, Readiness to Change and Smoking Expectancies Among Adult Male 
Substance Users Currently in Substance Use Treatment, is being conducted at St. Christopher’s. The 
study aims to identify changes in smoking expectancies and readiness to quit smoking among adult males 
in substance use treatment.  
 
The health information that we may use or disclose (release) for this research includes: 
  
 The current study will use information pertaining to a participant’s substance use and mental 
health history that will be collected from medical chart records through St. Christopher’s online charting 
system.  
 
The health information listed above may be used by and/or disclosed (released) to: The Copeland 
Smoking and Substance Use Clinical Research Lab.  
 
St. Christopher’s is required by law to protect your health information. By signing this document, you 
authorize St. Christopher’s to use and/or disclose (release) your health information for this research. 
Those persons who receive your health information may not be required by Federal privacy laws (such as 
the Privacy Rule) to protect it and may share your information with others without your permission, if 
permitted by laws governing them. 
 
Please note that St. Christopher’s may not condition (withhold or refuse) treating you on whether you sign 
this Authorization.  
 
Please note that you may change your mind and revoke (take back) this Authorization at any time, except 
to the extent that St. Christopher’s has already acted based on this Authorization. To revoke this 
Authorization, you must write to:  
 St. Christopher's Addiction Wellness Center 
 150 Cora Drive 
 Baton Rouge, LA 70815 
 (225) 387-1611  
 
This Authorization does not have an expiration date. 
 
_________________________     _________________________ 
Signature of participant or participant’s    Date 
personal representative 
 
_________________________     _________________________ 
Printed name of participant or     If applicable, a description of the 
participant’s personal representative    personal representative’s authority to 
        sign for the participant  
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APPENDIX C. THE RAPID ESTIMATE OF ADULT LITERACY IN MEDICINE —
SHORT FORM 
 
 
Patient ID #: ________________________     Date: ___________  
 
 
Behavior _____  
 
Exercise _____  
 
Menopause _____  
 
Rectal _____  
 
Antibiotics _____  
 
Anemia _____  
 
Jaundice _____  
 
 
 
 
TOTAL SCORE ______   
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APPENDIX D. DEMOGRAPHIC AND SMOKING QUESTIONNAIRE 
 
TO BE COMPLETED BY RESEARCHER 
 
Date:         
 
Participant ID#:       
 
Assessment #:         
 
Treatment (Primary, EC, IOP, 12-Step):       
 
Carbon Monoxide Monitor Reading:      
 
TO BE COMPLETED BY PARTICIPANT 
 
1. Age: ________   2. Sex (circle one) MALE  FEMALE 
 
3. Highest level of education completed (in years): __________ 
 
4. Annual household income: __________ 
 
5. What is your current employment status? (circle one) 
 a. Unemployed 
 b. Part-time employed 
 c. Full-time employed 
 
6. With which ethnic/ racial group do you most identify yourself? (circle one) 
 a. Caucasian   
 b. African-American   
 c. Asian 
 d. Hispanic 
 e. Other 
 
7. How often do you smoke? (circle one) 
 a. Daily 
 b. Weekly 
 c. Monthly 
 d. Yearly 
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8. Do you smoke cigarettes every day? (circle one)   
 a. Yes  
 b. No 
  
 (If YES, please answer question #9-10. 
 If NO, please skip to #11) 
 
9. How many years have you been smoking daily? __________ 
 
10. How many cigarettes per day do you smoke on average? __________ 
 
11. How many serious attempts (at least 24 hours) have you made to quit smoking PRIOR to  
 
entering St. Christopher’s substance use treatment center? ____________ 
 
12. How many serious attempts (at least 24 hours) have you made to quit smoking SINCE you  
 
have been in substance use treatment at St. Christopher’s? ____________ 
 
13. Do you use any type of electronic cigarette or vape? (circle one)  
 a. Yes 
 b. No 
 
14. Do you use any other types of smokeless tobacco (e.g., chewing tobacco)? (circle one) 
 a. Yes 
 b. No 
 
15. How are you currently paying for substance use treatment at St. Christopher’s? (circle one) 
 a. Medicaid/Medicare 
 b. Private health insurance 
 c. Out of pocket 
 
 
  
 
 64 
APPENDIX E. SUBSTANCE USE AND MENTAL HEALTH FORM 
 
TO BE TAKEN FROM PSYCHOSOCIAL ASSESSMENT IN PATIENT CHART: 
 
1.When was last use of any substance? __________   
 
2. What was last substance used prior to entering treatment? ___________ 
 
3. What is substance of choice? __________ 
 
4. Age of first use and substance used: ___________________ 
 
5. Number of treatment centers attended: __________ 
 
6. Longest period of completed abstinence from substances: __________ 
 
7. Substances used during month prior to admission to substance use treatment (circle below): 
  
 a. Alcohol   f. Amphetamines  j. Hallucinogens 
 b. Cannabis   g. Opiates   k. Ecstasy 
 c. Cocaine (crack)  h. Benzodiazepines  l. Bath salts 
 d. Cocaine (powder)  i. Inhalants 
 e. Methamphetamine  k. steroids    
 
8. Current suicidal ideation?   YES NO 
 
9. Past suicidal ideation?  YES NO 
 
10. Mental health treatment  
 
 Date: __________  Condition being treated: ___________________ 
  
 Date: __________  Condition being treated: ___________________  
 
 Date: __________  Condition being treated: ___________________  
  
 Date: __________  Condition being treated: ___________________  
  
 Date: __________  Condition being treated: ___________________   
  
 Date: __________  Condition being treated: ___________________  
 
 
 
 
 
 
 65 
11. Medications 
 
 Current medication: _________________ 
  
 Current medication: _________________ 
  
 Current medication: _________________ 
  
 Current medication: _________________ 
 
12. DSM – 5 Criteria for Substances of Choice 
 
 Substance use disorder: ____________________ Severity: __________________ 
 
 Substance use disorder: ____________________ Severity: __________________ 
 
TO BE TAKEN FROM PSYCHIATRIST OR NURSE PRACTITIONER NOTE IN 
PATIENT CHART: 
 
Substance use disorders present: 
  
 Substance use disorder: ____________________ Severity: __________________ 
 
 Substance use disorder: ____________________ Severity: __________________ 
 
 Substance use disorder: ____________________ Severity: __________________ 
 
 Substance use disorder: ____________________ Severity: __________________ 
 
 
Other psychological disorders present: 
 
 Disorder: ____________________ Severity: __________________ 
 
 Disorder: ____________________ Severity: __________________ 
 
 Disorder: ____________________ Severity: __________________ 
 
 Disorder: ____________________ Severity: __________________ 
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APPENDIX F. UNIVERSITY OF RHODE ISLAND STAGES OF CHANGE 
ASSESSMENT  
 
Please indicate the extent to which you tend to agree or disagree with each statement. In each 
case, make your choice in terms of how you feel right now, not what you have felt in the past or 
would like to feel.  
 
For all the statements that refer to your “problem”, answer in terms of your smoking. And “here” 
refers to the place of treatment. 
 
There are FIVE possible responses to each of the items in the questionnaire: 
1 = Strongly Disagree   2 = Disagree   3 = Undecided   4 = Agree   5 = Strongly Agree 
 
1. As far as I’m concerned, I don’t have any problems that need 
changing. 
_____ 
2. I think I might be ready for some self-improvement. _____ 
3. I am doing something about the problems that had been bothering 
me. 
_____ 
4. It might be worthwhile to work on my problem. _____ 
5. I’m not the problem one. It doesn’t make much sense for me to be 
here. 
_____ 
6. It worries me that I might slip back on a problem I have already 
changed, so I am here to seek help. 
_____ 
7. I am finally doing some work on my problem. _____ 
8. I’ve been thinking that I might want to change something about 
myself. 
_____ 
9. I have been successful in working on my problem but I’m not sure I 
can keep up the effort on my own. 
_____ 
10. At times my problem is difficult, but I’m working on it. _____ 
11. Being here is pretty much a waste of time for me because the 
problem doesn’t have to do with me. 
_____ 
12. I’m hoping this place will help me to better understand myself. _____ 
13. I guess I have faults, but there’s nothing that I really need to change. _____ 
14. I am really working hard to change. _____ 
15. I have a problem and I really think I should work at it. _____ 
16. I’m not following through with what I had already changed as well 
as I had hoped, and I’m here to prevent a relapse of the problem. 
_____ 
17. Even though I’m not always successful in changing, I am at least 
working on my problem. 
_____ 
18. I thought once I had resolved my problem I would be free of it, but 
sometimes I still find myself struggling with it. 
_____ 
19. I wish I had more ideas on how to solve the problem. _____ 
20. I have started working on my problems but I would like help. _____ 
21. Maybe this place will be able to help me. _____ 
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22. I may need a boost right now to help me maintain the changes I’ve 
already made. 
_____ 
23. I may be part of the problem, but I don’t really think I am. _____ 
24. I hope that someone here will have some good advice for me. _____ 
25. Anyone can talk about changing; I’m actually doing something about 
it. 
_____ 
26. All this talk about psychology is boring. Why can’t people just forget 
about their problems? 
_____ 
27. I’m here to prevent myself from having a relapse of my problem. _____ 
28. It is frustrating, but I feel I might be having a recurrence of a 
problem I thought I had resolved. 
_____ 
29. I have worries but so does the next guy. Why spend time thinking 
about them? 
_____ 
30. I am actively working on my problem. _____ 
31. I would rather cope with my faults than try to change them. _____ 
32. After all I had done to try to change my problem, every now and 
again it comes back to haunt me. 
_____ 
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APPENDIX G. SMOKING CONSEQUENCES QUESTIONNAIRE – ADULT  
 
Instructions: This questionnaire is designed to assess beliefs people have about the consequences of smoking a 
cigarette.  We are interested in your general expectations about the consequences of your smoking.  Below is a list 
of statements.  Each statement contains a possible consequence of smoking.  For each of the statements listed below, 
please rate how LIKELY or UNLIKELY you believe each consequence is for you when you smoke.  If the 
consequence seems LIKELY to you, circle a number from 5-9.  That is, if you believe that a consequence would 
never happen, circle 0; if you believe a consequence would happen every time you smoke, circle 9.  Use the guide 
below to aid you further.  For example, if a consequence seems completely likely to you, you would circle 9.  If it 
seems a little unlikely to you, you would circle 4. 
 
 0 1 2 3 4 5 6 7 8 9 
     Completely             Very            A little     A little                 Very        Completely 
         Extremely              Somewhat              Somewhat           Extremely 
-----------------UNLIKELY------------------------X-----------------------LIKELY------------------ 
 
           UNLIKELY                LIKELY 
1. Cigarettes taste good.       0     1     2     3     4     5     6     7     8     9 
 
2. Smoking controls my appetite.             0     1     2     3     4     5     6     7     8     9 
 
3. My throat burns after smoking.             0     1     2     3     4     5     6     7     8     9 
 
4. Cigarettes help me deal with anxiety or worry.            0     1     2     3     4     5     6     7     8     9 
 
5. Nicotine “fits” can be controlled by smoking.             0     1     2     3     4     5     6     7     8     9 
 
6. When I’m angry, a cigarette can calm me down.             0     1     2     3     4     5     6     7     8     9 
 
7. When I’m alone, a cigarette can help me pass the time.            0     1     2     3     4     5     6     7     8     9 
 
8. I become more addicted the more I smoke.             0     1     2     3     4     5     6     7     8     9 
 
9. If I’m tense, a cigarette helps me to relax.             0     1     2     3     4     5     6     7     8     9 
 
10. Cigarettes keep me from overeating.              0     1     2     3     4     5     6     7     8     9 
 
11. Smoking a cigarette energizes me.             0     1     2     3     4     5     6     7     8     9 
 
12. Cigarettes help me deal with anger.              0     1     2     3     4     5     6     7     8     9 
 
13. Smoking calms me down when I feel nervous.             0     1     2     3     4     5     6     7     8     9 
 
14. Cigarettes make my lungs hurt.      0     1     2     3     4     5     6     7     8     9 
 
15. I feel like I do a better job when I am smoking.            0     1     2     3     4     5     6     7     8     9 
 
16. A cigarette can give me energy when I’m bored and tired.            0     1     2     3     4     5     6     7     8     9 
 
17. Cigarettes can really make me feel good.             0     1     2     3     4     5     6     7     8     9 
 
18. When I’m feeling happy, smoking helps me keep that feeling.            0     1     2     3     4     5     6     7     8     9 
 
19. I will enjoy the flavor of a cigarette.              0     1     2     3     4     5     6     7     8     9 
 
20. If I have nothing to do, a smoke can help kill time.             0     1     2     3     4     5     6     7     8     9 
 
21. I will enjoy feeling a cigarette on my tongue and lips.            0     1     2     3     4     5     6     7     8     9 
 
22. Smoking will satisfy my nicotine cravings.             0     1     2     3     4     5     6     7     8     9 
      
23. I feel like part of a group when I’m around other smokers.            0     1     2     3     4     5     6     7     8     9  
                
24. Smoking makes me seem less attractive.             0     1     2     3     4     5     6     7     8     9 
 
25. By smoking, I risk heart disease and lung cancer.           0     1     2     3     4     5     6     7     8     9 
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26. Smoking makes me enjoy people more.              0     1     2     3     4     5     6     7     8     9 
 
27. Cigarettes help me reduce or handle tension.             0     1     2     3     4     5     6     7     8     9 
 
28. I feel better physically after having a cigarette.             0     1     2     3     4     5     6     7     8     9 
 
29. I enjoy parties more when I am smoking.            0     1     2     3     4     5     6     7     8     9 
 
30. People think less of me if they see me smoking.            0     1     2     3     4     5     6     7     8     9 
 
31. A cigarette can satisfy my urge to smoke.             0     1     2     3     4     5     6     7     8     9 
 
32. Just handling a cigarette is pleasurable.              0     1     2     3     4     5     6     7     8     9 
 
33. If I’m feeling irritable, a smoke will help me relax.             0     1     2     3     4     5     6     7     8     9 
 
34. Smoking irritates my mouth and throat.              0     1     2     3     4     5     6     7     8     9 
 
35. When I feel bored and tired, a cigarette can really help.            0     1     2     3     4     5     6     7     8     9 
 
36. I will become more dependent on nicotine if I continue smoking.          0     1     2     3     4     5     6     7     8     9 
 
37. Smoking helps me control my weight.              0     1     2     3     4     5     6     7     8     9 
 
38. When I’m upset with someone, a cigarette helps me cope.            0     1     2     3     4     5     6     7     8     9 
 
39. The more I smoke, the more I risk my health.             0     1     2     3     4     5     6     7     8     9 
 
40. Cigarettes keep me from eating more than I should.            0     1     2     3     4     5     6     7     8     9 
 
41. I enjoy the steps I take to light up.              0     1     2     3     4     5     6     7     8     9 
 
42. Conversations seem more special if we are all smoking.            0     1     2     3     4     5     6     7     8     9 
 
43. I look ridiculous while smoking.              0     1     2     3     4     5     6     7     8     9 
 
44. Smoking keeps my weight down.              0     1     2     3     4     5     6     7     8     9 
 
45. I like the way a cigarette makes me feel physically.             0     1     2     3     4     5     6     7     8     9 
 
46. Smoking is hazardous to my health.              0     1     2     3     4     5     6     7     8     9 
 
47. I enjoy feeling the smoke hit my mouth and the back of my throat.             0     1     2     3     4     5     6     7     8     9 
 
48. When I smoke, the taste is pleasant.             0     1     2     3     4     5     6     7     8     9 
 
49. I like to watch the smoke from my cigarette.             0     1     2     3     4     5     6     7     8     9 
 
50. When I am worrying about something, a cigarette is helpful.            0     1     2     3     4     5     6     7     8     9 
 
51. Smoking temporarily reduces those repeated urges for cigarettes.           0     1     2     3     4     5     6     7     8     9 
 
52. I enjoy the taste sensations while smoking.             0     1     2     3     4     5     6     7     8     9 
 
53. I feel more at ease with other people if I have a cigarette.            0     1     2     3     4     5     6     7     8     9 
 
54. Cigarettes are good for dealing with boredom.             0     1     2     3     4     5     6     7     8     9 
 
55. Smoking is taking years off my life.              0     1     2     3     4     5     6     7     8     9 
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APPENDIX H. FAGERSTRÖM TEST FOR NICOTINE DEPENDENCE  
 
1. How soon after you wake up do you smoke your first cigarette? 
 a. Within 5 minutes 
 b. 6-30 minutes 
 c. 31-60 minutes 
 d. After 60 minutes 
 
2. Do you find it difficult to refrain from smoking in places where it is forbidden e.g., in church, 
at the library, in the cinema, etc.? 
 a. Yes 
 b. No 
 
3. Which cigarette would you hate most to give up? 
 a. The first one in the morning 
 b. All others 
 
4. How many cigarettes do you smoke a day? 
 a. 10 or less 
 b. 11-20 
 c. 21-30 
 d. 31 or more 
 
5. Do you smoke more frequently during the first hours after waking than during the rest of the 
day? 
 a. Yes 
 b. No 
 
6. Do you smoke if you are so ill that you are in bed most of the day? 
 a. Yes 
 b. No 
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